# 2026年2月10日 - 专业文献速递

本期速递为您整理了最新的科研文献及AI评价，每一篇文献都包含了详细的元数据、原文摘要、中文翻译和AI的专业点评，敬请参考。

---

## 1. ARID1A 介导独立于 SWI/SNF 的异染色质结构维持，以抑制结肠癌中的病毒模拟和免疫原性

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41661654)
**期刊：** Cancer research
**PMID：** 41661654
**DOI：** 10.1158/0008-5472.CAN-25-3231

### 第一部分 原文与翻译

**英文原标题：** ARID1A Mediates SWI/SNF-Independent Maintenance of Heterochromatin Architecture to Restrain Viral Mimicry and Immunogenicity in Colon Cancer.

> **英文摘要：**
> ARID1A is a crucial subunit of the SWI/SNF chromatin-remodeling complex and is frequently mutated in human cancers. While its tumor-suppressive activity has been ascribed exclusively to SWI/SNF-dependent chromatin remodeling, we established here a SWI/SNF-independent role of ARID1A in safeguarding heterochromatin architecture to silence viral mimicry and restrain immunogenicity in colorectal cancer. ARID1A deficiency triggered viral mimicry and enhanced immunogenicity in both microsatellite stable and instable contexts. Mechanistically, ARID1A interacted with TRIM28 to preserve heterochromatin rigidity. Loss of ARID1A displaced SETDB1 from the TRIM28-containing heterochromatin complex, leading to the reversal of H3K9me3-mediated repression at endogenous retroelement regions. The release of these elements triggered viral mimicry, exemplified by enhanced type I interferon-mediated immune responses. Notably, disrupting the ARID1A-TRIM28 interaction with synthetic peptides induced a viral mimicry phenotype in ARID1A wildtype tumors, converting immunologically "cold" lesions into T-cell-inflamed microenvironments and suppressing tumor growth. Both cytosolic RNA and DNA sensors were required for the ensuing interferon response and for the heightened sensitivity to PD-1 blockade elicited by ARID1A deficiency. These findings thus reveal an unanticipated heterochromatin gatekeeper function of ARID1A that operates outside the SWI/SNF complex and can be exploited to potentiate immune checkpoint therapy activity.

> **中文摘要：**
> ARID1A 是 SWI/SNF 染色质重塑复合物的关键亚基，在人类癌症中经常发生突变。虽然其抑癌活性一直被认为完全归功于依赖 SWI/SNF 的染色质重塑，但我们在本文中确立了 ARID1A 在维护异染色质结构中的非 SWI/SNF 依赖性作用，用以沉默结直肠癌中的病毒模拟并抑制免疫原性。ARID1A 缺失在微卫星稳定和不稳定背景下均能触发病毒模拟并增强免疫原性。从机制上讲，ARID1A 与 TRIM28 相互作用以保持异染色质的刚性。ARID1A 的缺失导致 SETDB1 从含有 TRIM28 的异染色质复合物中解离，从而导致内源性逆转录元件区域 H3K9me3 介导的抑制发生逆转。这些元件的释放触发了病毒模拟，典型表现为增强的 I 型干扰素介导的免疫反应。值得注意的是，利用合成肽破坏 ARID1A-TRIM28 的相互作用可诱导 ARID1A 野生型肿瘤产生病毒模拟表型，将免疫“冷”病灶转变为 T 细胞浸润的炎症微环境并抑制肿瘤生长。随后的干扰素反应以及由 ARID1A 缺失引起的对 PD-1 阻断治疗敏感性的提高，均需要胞质 RNA 和 DNA 传感器的参与。因此，这些发现揭示了 ARID1A 一项意想不到的异染色质“守门人”功能，该功能在 SWI/SNF 复合物之外运行，可被用于增强免疫检查点治疗的活性。

### 第二部分 AI 大师评价

该研究挑战了 ARID1A 仅通过 SWI/SNF 复合物发挥抑癌作用的传统认知，揭示了其作为异染色质“守门人”的新功能。研究通过分子机制证明 ARID1A 与 TRIM28 协作维持 H3K9me3 介导的基因沉默，其缺失引发的内源性逆转录元件释放可触发病毒模拟效应并激活免疫反应。创新之处在于利用合成肽阻断该通路，成功将免疫“冷”肿瘤转变为“热”肿瘤，为提升 PD-1 抑制剂在 ARID1A 野生型结直肠癌中的疗效提供了极具临床转化潜力的策略。

---

## 2. 法尼基转移酶抑制剂 darlifarnib (KO-2806) 使复发肿瘤重新对 RAS 抑制产生敏感性

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41661652)
**期刊：** Cancer research
**PMID：** 41661652
**DOI：** 10.1158/0008-5472.CAN-25-2764

### 第一部分 原文与翻译

**英文原标题：** The farnesyl transferase inhibitor darlifarnib (KO-2806) re-sensitizes relapsing tumors to RAS inhibition.

> **英文摘要：**
> Resistance remains a key issue limiting the clinical benefit from RAS-targeting therapeutic agents and necessitates combination approaches. Here, we identified persistent mTORC1 activity in preclinical KRAS-mutant non-small cell lung cancer (NSCLC) and colorectal cancer (CRC) models as a frequent, nongenetic driver of inherent and adaptive resistance to RAS inhibition. This vulnerability was targetable with the farnesyl transferase inhibitor darlifarnib (KO-2806), which blocks mTORC1 activation via RHEB while sparing mTORC2 to limit associated toxicities. The addition of KO-2806 to NSCLC or CRC tumors progressing on mutant-selective RAS inhibitors led to rapid and durable tumor regression. In contrast, switching from mutant-selective to pan-RAS inhibitor monotherapy resulted in only stasis of NSCLC tumors and had no effect on CRC tumor progression. Further, the addition of KO-2806 rescued sensitivity of progressing tumors to the pan-RAS inhibitor RMC-6236. These results establish mTORC1 as an important mediator of escape from RAS inhibition and highlight KO-2806 as a promising RAS companion inhibitor in patients with prior RAS inhibitor exposure.

> **中文摘要：**
> 耐药性仍然是限制 RAS 靶向治疗药物临床获益的关键问题，并需要联合治疗方案。在此，我们在临床前 KRAS 突变非小细胞肺癌 (NSCLC) 和结直肠癌 (CRC) 模型中确定，持续的 mTORC1 活性是导致对 RAS 抑制产生固有耐药和适应性耐药的常见非遗传驱动因素。这一弱点可通过法尼基转移酶抑制剂 darlifarnib (KO-2806) 进行靶向治疗，该药物通过 RHEB 阻断 mTORC1 的激活，同时保留 mTORC2 以限制相关的毒性。在对突变选择性 RAS 抑制剂产生耐药进展的 NSCLC 或 CRC 肿瘤中加入 KO-2806，可导致快速且持久的肿瘤消退。相比之下，从突变选择性抑制剂切换到泛 RAS (pan-RAS) 抑制剂单药治疗，仅能使 NSCLC 肿瘤处于稳定状态，且对 CRC 肿瘤进展没有影响。此外，加入 KO-2806 挽救了进展期肿瘤对泛 RAS 抑制剂 RMC-6236 的敏感性。这些结果确立了 mTORC1 是 RAS 抑制逃逸的重要介质，并突显了 KO-2806 作为曾接受过 RAS 抑制剂治疗患者的一种具有前景的 RAS 伴随抑制剂。

### 第二部分 AI 大师评价

本研究揭示了 mTORC1 持续激活是 KRAS 突变肿瘤对 RAS 靶向药物产生耐药的关键非遗传机制。通过引入法尼基转移酶抑制剂 darlifarnib (KO-2806)，研究成功阻断了由 RHEB 介导的 mTORC1 通路逃逸，且由于保留了 mTORC2 功能而表现出良好的安全性。该研究在临床前模型中显著逆转了对选择性和泛 RAS 抑制剂的耐药，为既往治疗失败的 RAS 突变癌症患者提供了一种极具潜力的联合用药新策略。

---

## 3. 一种靶向 MERTK 的抗体偶联药物可选择性清除 M2 型肿瘤相关巨噬细胞和表达 MERTK 的癌细胞

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41661650)
**期刊：** Cancer research
**PMID：** 41661650
**DOI：** 10.1158/0008-5472.CAN-25-2998

### 第一部分 原文与翻译

**英文原标题：** A MERTK-Targeting Antibody-Drug Conjugate Selectively Depletes M2 Tumor-Associated Macrophages and MERTK-Expressing Cancer Cells.

> **英文摘要：**
> MERTK is a receptor tyrosine kinase predominantly expressed on M2 macrophages that plays a critical role in the clearance of apoptotic cells and maintenance of an immune-suppressive phenotype. M2 macrophages are highly abundant in the tumor microenvironment where they facilitate tumor progression and resistance to immunotherapy. MERTK is also overexpressed in cancer cells, where it can drive cancer survival and metastasis through induction of proliferation and anti-apoptotic signaling programs. Here we developed an antibody-drug conjugate (ADC) that simultaneously targets MERTK-expressing M2 tumor associated macrophages and cancer cells. The ADC comprised the monoclonal antibody RGX-019 that binds human MERTK, combined with a monomethyl auristatin E (MMAE) toxic payload. The unconjugated antibody had intrinsic activity to suppress M2 cytokine expression by macrophages, block in vitro colony formation of cancer cells, and inhibit in vivo tumor growth and metastasis. When MMAE was conjugated to the antibody, the ADC exhibited superior in vitro cytotoxicity and in vivo anti-tumor efficacy in MERTK-expressing tumors. Tumor growth inhibition in humanized mice was associated with depletion of tumor-associated M2 macrophages. Furthermore, unlike other MERTK-targeting small molecules or antibodies, no retinal toxicity of RGX-019-MMAE was observed in vivo. These findings reveal that combined therapeutic targeting of MERTK in cancer cells and M2 macrophages offers enhanced opportunities for anti-tumor efficacy in a wide range of MERTK-expressing tumors.

> **中文摘要：**
> MERTK 是一种主要在 M2 型巨噬细胞上表达的受体酪氨酸激酶，在清除凋亡细胞和维持免疫抑制表型方面发挥着至关重要作用。M2 型巨噬细胞在肿瘤微环境中含量极高，在此它们促进肿瘤进展并产生对免疫疗法的耐药性。MERTK 在癌细胞中也过度表达，可通过诱导增殖和抗凋亡信号程序来驱动癌症存活和转移。在此，我们开发了一种同时靶向表达 MERTK 的 M2 型肿瘤相关巨噬细胞和癌细胞的抗体偶联药物（ADC）。该 ADC 由结合人类 MERTK 的单克隆抗体 RGX-019 与单甲基奥瑞他汀 E（MMAE）毒性载荷组成。未偶联的抗体具有抑制巨噬细胞表达 M2 细胞因子、阻断癌细胞体外集落形成以及抑制体内肿瘤生长和转移的内在活性。当 MMAE 偶联到抗体上时，该 ADC 在表达 MERTK 的肿瘤中表现出优异的体外细胞毒性和体内抗肿瘤疗效。人源化小鼠中的肿瘤生长抑制作用与肿瘤相关 M2 型巨噬细胞的清除有关。此外，与其它靶向 MERTK 的小分子或抗体不同，RGX-019-MMAE 在体内未观察到视网膜毒性。这些发现表明，联合治疗性靶向癌细胞和 M2 型巨噬细胞中的 MERTK，为在广泛的表达 MERTK 的肿瘤中增强抗肿瘤疗效提供了更多机会。

### 第二部分 AI 大师评价

该研究成功开发并验证了靶向 MERTK 的抗体偶联药物 RGX-019-MMAE，其核心创新点在于实现了对 M2 型肿瘤相关巨噬细胞（TAMs）和 MERTK 阳性癌细胞的双重打击。实验证明该 ADC 能够有效重塑肿瘤免疫微环境并直接杀伤肿瘤，在多种模型中表现出显著的生长抑制和抗转移作用。值得注意的是，该药物规避了以往 MERTK 抑制剂常见的视网膜毒性风险，为治疗 MERTK 阳性恶性肿瘤提供了一种高效且更安全的临床转化方案。

---

## 4. 空间多组学分析揭示糖尿病通过刺激胆固醇诱导的中性粒细胞胞外陷阱形成来促进胰腺癌进展

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41661642)
**期刊：** Cancer research
**PMID：** 41661642
**DOI：** 10.1158/0008-5472.CAN-25-2854

### 第一部分 原文与翻译

**英文原标题：** Spatial Multi-omics Analyses Reveal Diabetes Promotes Pancreatic Cancer Progression by Stimulating Cholesterol-Induced Neutrophil Extracellular Trap Formation.

> **英文摘要：**
> Pancreatic ductal adenocarcinoma (PDAC) patients with diabetes mellitus (DM) exhibit poor clinical outcomes. Metabolic reprogramming of both cancer cells and immune compartments plays a crucial role in shaping the anti-tumor immune response in PDAC. DM-induced metabolic alteration may disrupt the intricate crosstalk between immune cells and tumor-associated immune factors, profoundly influencing PDAC progression. Here, we performed an integrated, spatially resolved multi-omics study to investigate DM-associated, cell-speciﬁc metabolic remodeling within the PDAC tumor microenvironment. DM influenced interactions between tumor cells and immune cells, which accelerated PDAC growth in both humans and mice. PDAC patients with DM exhibited higher tumor-stage, poorer differentiation, and worse outcomes. Spatial metabolic and transcriptional profiling revealed that SREBP2-dependent cholesterol biosynthesis exacerbated PDAC progression. Increased cholesterol biosynthesis promoted neutrophil recruitment and accelerated formation of neutrophil extracellular traps (NETs) by stimulating the CXCL1-CXCR1/CXCR2 signaling axis, ultimately promoting PDAC growth. Inhibition of SREBP2, pharmacological blockade of CXCL1, or perturbation of NETs markedly reduced PDAC growth in diabetic mouse models. Together, these multi-omics analyses and follow-up mechanistic studies constitute an integrated approach that elucidates a metabolic mechanism by which diabetes promotes PDAC development by remodeling the tumor immune microenvironment and highlights a potential therapeutic strategy for PDAC with DM.

> **中文摘要：**
> 患有糖尿病（DM）的胰腺导管腺癌（PDAC）患者临床预后较差。癌细胞和免疫区的代谢重编程在塑造PDAC抗肿瘤免疫反应中起着关键作用。DM诱导的代谢改变可能会破坏免疫细胞与肿瘤相关免疫因子之间错综复杂的串扰，从而深刻影响PDAC的进展。在此，我们进行了一项综合的、空间分辨率的多组学研究，以调查PDAC肿瘤微环境内与DM相关的细胞特异性代谢重塑。DM影响了肿瘤细胞与免疫细胞之间的相互作用，从而加速了人类和小鼠体内的PDAC生长。患有DM的PDAC患者表现出更高的肿瘤分期、更差的分化程度以及更糟的预后。空间代谢和转录组分析显示，SREBP2依赖性的胆固醇生物合成加剧了PDAC的进展。增加的胆固醇生物合成通过刺激CXCL1-CXCR1/CXCR2信号轴，促进中性粒细胞募集并加速中性粒细胞胞外陷阱（NETs）的形成，最终促进PDAC生长。在糖尿病小鼠模型中，抑制SREBP2、对CXCL1进行药理学阻断或干扰NETs可显著降低PDAC的生长。总之，这些多组学分析和后续的机制研究构成了一种综合方法，阐明了糖尿病通过重塑肿瘤免疫微环境促进PDAC发展的代谢机制，并突出了针对伴有DM的PDAC的潜在治疗策略。

### 第二部分 AI 大师评价

本研究通过先进的空间多组学技术，深刻揭示了糖尿病（DM）驱动胰腺导管腺癌（PDAC）进展的代谢免疫机制。研究核心发现DM能诱导SREBP2依赖的胆固醇合成增强，通过CXCL1轴触发中性粒细胞胞外陷阱（NETs）的形成，从而构建利于肿瘤生长的微环境。该研究不仅阐明了DM患者PDAC预后不良的分子基础，还通过动物模型验证了针对SREBP2及NETs的治疗潜力，具有极高的临床指导意义和科学创新性。

---

## 5. 咖啡和茶摄入量、痴呆风险与认知功能

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41661604)
**期刊：** JAMA
**PMID：** 41661604
**DOI：** 10.1001/jama.2025.27259

### 第一部分 原文与翻译

**英文原标题：** Coffee and Tea Intake, Dementia Risk, and Cognitive Function.

> **英文摘要：**
> IMPORTANCE: Evidence linking coffee and tea to cognitive health remains inconclusive, and most studies fail to differentiate caffeinated from decaffeinated coffee. OBJECTIVE: To investigate associations of coffee and tea intake with dementia risk and cognitive function. DESIGN, SETTING, AND PARTICIPANTS: Prospective cohort study that included female participants from the Nurses' Health Study (NHS; n = 86 606 with data from 1980-2023) and male participants from the Health Professionals Follow-up Study (HPFS; n = 45 215 with data from 1986-2023) who did not have cancer, Parkinson disease, or dementia at study entry (baseline) in the US. EXPOSURES: The primary exposures were intakes of caffeinated coffee, decaffeinated coffee, and tea. Dietary intake was collected every 2 to 4 years using validated food frequency questionnaires. MAIN OUTCOMES AND MEASURES: The primary outcome was dementia, which was identified via death records and physician diagnoses. The secondary outcomes included subjective cognitive decline assessed by a questionnaire-based score (range, 0-7; higher scores indicate greater perceived decline; cases defined as those with a score ≥3) and objective cognitive function assessed only in the NHS cohort using telephone-based neuropsychological tests such as the Telephone Interview for Cognitive Status (TICS) score (range, 0-41) and a measure of global cognition (a standardized mean z score for all 6 administered cognitive tests). RESULTS: Among 131 821 participants (mean age at baseline, 46.2 [SD, 7.2] years in the NHS cohort and 53.8 [SD, 9.7] years in the HPFS cohort; 65.7% were female) during up to 43 years of follow-up (median, 36.8 years; IQR, 28-42 years), there were 11 033 cases of incident dementia. After adjusting for potential confounders and pooling results across cohorts, higher caffeinated coffee intake was significantly associated with lower dementia risk (141 vs 330 cases per 100 000 person-years comparing the fourth [highest] quartile of consumption with the first [lowest] quartile; hazard ratio, 0.82 [95% CI, 0.76 to 0.89]) and lower prevalence of subjective cognitive decline (7.8% vs 9.5%, respectively; prevalence ratio, 0.85 [95% CI, 0.78 to 0.93]). In the NHS cohort, higher caffeinated coffee intake was also associated with better objective cognitive performance. Compared with participants in the lowest quartile, those in the highest quartile had a higher mean TICS score (mean difference, 0.11 [95% CI, 0.01 to 0.21]) and a higher mean global cognition score (mean difference, 0.02 [95% CI, -0.01 to 0.04]); however, the association with global cognition was not statistically significant (P = .06). Higher intake of tea showed similar associations with these cognitive outcomes, whereas decaffeinated coffee intake was not associated with lower dementia risk or better cognitive performance. A dose-response analysis showed nonlinear inverse associations of caffeinated coffee and tea intake levels with dementia risk and subjective cognitive decline. The most pronounced associated differences were observed with intake of approximately 2 to 3 cups per day of caffeinated coffee or 1 to 2 cups per day of tea. CONCLUSIONS AND RELEVANCE: Greater consumption of caffeinated coffee and tea was associated with lower risk of dementia and modestly better cognitive function, with the most pronounced association at moderate intake levels.

> **中文摘要：**
> 重要性：将咖啡和茶与认知健康联系起来的证据仍无定论，且大多数研究未能区分含咖啡因咖啡和脱咖啡因咖啡。
> 
> 目的：调查咖啡和茶的摄入量与痴呆风险及认知功能之间的关联。
> 
> 设计、场所和受试者：这项前瞻性队列研究纳入了来自美国护士健康研究（NHS；n=86,606，数据覆盖1980-2023年）的女性受试者和来自健康专业人员随访研究（HPFS；n=45,215，数据覆盖1986-2023年）的男性受试者，这些受试者在入组（基线）时均未患有癌症、帕金森病或痴呆。
> 
> 暴露因素：主要暴露因素为含咖啡因咖啡、脱咖啡因咖啡和茶的摄入量。饮食摄入量通过经过验证的食物频率问卷每2至4年收集一次。
> 
> 主要结局和测量指标：主要结局是痴呆，通过死亡记录和医生诊断确定。次要结局包括通过问卷评分评估的主观认知衰退（评分范围0-7；得分越高表示感知的衰退越严重；评分≥3定义为病例），以及仅在NHS队列中通过基于电话的神经心理学测试评估的客观认知功能，例如认知状态电话访谈（TICS）评分（范围0-41）和全球认知测量（所有6项认知测试的标准平均z分）。
> 
> 结果：在131,821名受试者中（基线平均年龄：NHS队列为46.2岁，HPFS队列为53.8岁；65.7%为女性），在长达43年的随访期间（中位数为36.8年；四分位距为28-42年），共记录了11,033例新发痴呆病例。在调整潜在混杂因素并汇总队列结果后，较高的含咖啡因咖啡摄入量与较低的痴呆风险（对比最高摄入四分位数与最低四分位数，发病率分别为141 vs 330例/10万人年；风险比为0.82 [95% CI, 0.76至0.89]）和较低的主观认知衰退患病率（分别为7.8% vs 9.5%；患病率比为0.85 [95% CI, 0.78至0.93]）显著相关。在NHS队列中，较高的含咖啡因咖啡摄入量也与较好的客观认知表现相关。与最低四分位组相比，最高四分位组受试者的平均TICS得分更高（平均差为0.11 [95% CI, 0.01至0.21]），平均全球认知得分也更高（平均差为0.02 [95% CI, -0.01至0.04]）；然而，与全球认知的关联未达到统计学显著性（P = .06）。茶的高摄入量与这些认知结局表现出相似的关联，而脱咖啡因咖啡的摄入量与痴呆风险降低或认知表现改善无关。剂量-反应分析显示，含咖啡因咖啡和茶的摄入水平与痴呆风险和主观认知衰退呈非线性负相关。在每天摄入约2至3杯含咖啡因咖啡或1至2杯茶时，相关差异最为显著。
> 
> 结论和相关性：较高的含咖啡因咖啡和茶消费量与较低的痴呆风险和略好一些的认知功能相关，且在适度摄入水平下这种关联最为显著。

### 第二部分 AI 大师评价

这项基于NHS和HPFS两项大型前瞻性队列的大规模研究，提供了含咖啡因饮品与认知健康关联的高质量证据。研究不仅区分了咖啡因对神经保护的特异性贡献，还通过长达40余年的随访揭示了摄入量与痴呆风险间的非线性剂量反应关系。其发现适度摄入（咖啡2-3杯/天，茶1-2杯/天）获益最显著，具有极高的公共卫生指导价值，尽管对客观认知功能的提升效应相对微弱，但对降低痴呆发病率的长期影响不容忽视。

---

## 6. 在HER2阳性转移性乳腺癌中使用增强脑部CT进行主动脑部筛查的研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41661219)
**期刊：** Clinical cancer research : an official journal of the American Association for Cancer Research
**PMID：** 41661219
**DOI：** 10.1158/1078-0432.CCR-25-3557

### 第一部分 原文与翻译

**英文原标题：** Proactive brain screening using contrast-enhanced brain CT scans in HER2+ metastatic breast cancer.

> **英文摘要：**
> PURPOSE: According to recent EANO-ESMO guidelines, proactive brain imaging can be considered in asymptomatic patients with HER2+ metastatic breast cancer (mBC), due to high risk of developing brain metastases (BMs). However, optimal imaging modality and timing remain unclear. We retrospectively assessed the impact of contrast-enhanced CT screening on symptomatic BMs in HER2+ mBC patients. METHODS: Consecutive patients newly diagnosed with HER2+ mBC treated with trastuzumab-pertuzumab plus taxane (2014-2024) were retrospectively identified. Brain screening was defined as at least one contrast-enhanced brain CT scan per year without neurological symptoms during the first 2 years post-diagnosis. RESULTS: Among 148 identified patients, 73 underwent brain screening and 75 did not. Median number of annual brain CT scans during the first 2 years was 2.0 (IQR 1.2-2.5) and 0.0 (IQR 0.0-0.5) in the screening and non-screening groups, respectively. Thirty patients (20.3%) developed BMs during the first 2 years. Cumulative BM incidence was significantly higher in patients undergoing screening (30.6% vs 12.3%, Gray's p=0.004), but symptomatic BMs were significantly lower in patients undergoing screening (0% vs 9.5%, Gray's p=0.012). Patients undergoing screening had better preserved performance status at BM diagnosis (p=0.002) and a numerical trend toward fewer BMs (p=0.057). Treatment patterns post-BM diagnosis were similar, though WBRT was used less often in the screening group (14.3% vs 44.4%, p=0.073). CONCLUSIONS: Brain screening with CT scans was associated with fewer symptomatic BMs and better performance status at BM diagnosis, supporting proactive imaging in HER2+ mBC. Prospective studies are warranted to define optimal timing and imaging modalities.

> **中文摘要：**
> 目的：根据最新的EANO-ESMO指南，由于脑转移（BMs）发生风险高，对于无症状的HER2阳性（HER2+）转移性乳腺癌（mBC）患者可考虑进行主动脑部影像学检查。然而，最佳的影像学手段和时机仍不明确。本研究回顾性评估了增强CT筛查对HER2+ mBC患者症状性脑转移的影响。方法：回顾性纳入2014年至2024年间接受曲妥珠单抗-帕妥珠单抗联合紫杉类药物治疗的连续新诊断HER2+ mBC患者。脑部筛查定义为在诊断后的前2年内，在无神经系统症状的情况下，每年至少进行一次脑部增强CT扫描。结果：在识别出的148名患者中，73名接受了脑部筛查，75名未接受。在前2年内，筛查组和非筛查组的中位年度脑部CT扫描次数分别为2.0次（IQR 1.2-2.5）和0.0次（IQR 0.0-0.5）。30名患者（20.3%）在前2年内发生了脑转移。筛查组的累积脑转移发生率显著更高（30.6% vs 12.3%，Gray's p=0.004），但筛查组的症状性脑转移发生率显著更低（0% vs 9.5%，Gray's p=0.012）。接受筛查的患者在脑转移诊断时具有更好的体能状态（p=0.002），并呈现出脑转移病灶较少的数值趋势（p=0.057）。诊断脑转移后的治疗模式相似，尽管筛查组中全脑放疗（WBRT）的使用频率较低（14.3% vs 44.4%，p=0.073）。结论：使用CT扫描进行脑部筛查与更少的症状性脑转移以及诊断脑转移时更好的体能状态相关，这支持在HER2+ mBC中进行主动影像学检查。有必要开展前瞻性研究以确定最佳的筛查时机和影像学手段。

### 第二部分 AI 大师评价

本研究针对高风险的HER2阳性转移性乳腺癌群体，探讨了主动脑部CT筛查的临床获益。研究发现，尽管筛查组由于早期检出导致累积脑转移发生率看似更高，但却显著降低了症状性脑转移的风险，并使患者在确诊脑转移时保持更好的体力评分，减少了对全脑放疗的需求。尽管存在回顾性设计和CT对比MRI敏感度差异的局限性，该研究为落实EANO-ESMO指南中的主动筛查建议提供了重要的实证依据，强调了早期发现对优化患者生存质量的价值。

---

## 7. 多西他赛联合帕博利珠单抗及白细胞介素-12基因疗法治疗非转移性、蒽环类药物耐药三阴性乳腺癌的II期研究（INTEGRAL）。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41661218)
**期刊：** Clinical cancer research : an official journal of the American Association for Cancer Research
**PMID：** 41661218
**DOI：** 10.1158/1078-0432.CCR-25-2649

### 第一部分 原文与翻译

**英文原标题：** A phase II study of docetaxel and pembrolizumab plus Interleukin-12 gene therapy in non-metastatic, anthracycline-refractory triple negative breast cancer (INTEGRAL).

> **英文摘要：**
> PURPOSE: To evaluate the safety and efficacy of combining intra-tumoral IL-12 gene therapy with docetaxel and pembrolizumab in high-risk patients with early stage triple-negative breast cancer (TNBC) refractory to anthracycline-based neoadjuvant chemotherapy. METHODS: In this single-arm, open-label phase II trial, patients with stage I-III TNBC and residual disease after anthracycline therapy received neoadjuvant docetaxel (100 mg/m2 IV) and pembrolizumab (200 mg IV) every three weeks for four cycles. Intra-tumoral injections of adenoviral-mediated interleukin-12 (ADV/IL-12) gene therapy were administered three days prior to cycles 2-4. The primary endpoint was pathologic complete response (pCR). Secondary endpoints were safety and toxicity assessments. Correlative analyses included immune profiling and cytokine measurement. RESULTS: Eight patients were enrolled; half received ADV/IL-12 at a starting dose of 5 x 1011 viral particles (VP) in 2mL volume, injected into the breast tumor. Owing to adverse events (AE's), the remaining 4 patients received 3 x 1011 viral particles. The trial was terminated early due to toxicity, with 87.5% of patients experiencing grade ≥3 AE's, including two treatment-related deaths. Only one patient (12.5%) who received a lower dose of ADV/IL-12 achieved a pCR. Elevation of CCL4 levels was observed exclusively in the patient who achieved pCR. CONCLUSIONS: The combination of docetaxel, pembrolizumab, and intratumoral ADV/IL-12 is associated with high systemic toxicity and minimal efficacy. These results underscore the need for cautious dose optimization and patient selection when integrating immuno-potentiating cytokines into neoadjuvant regimens. Translational insights from this study inform safer design of future IL-12-based strategies in immune-refractory TNBC.

> **中文摘要：**
> 目的：评估瘤内注射IL-12基因疗法联合多西他赛和帕博利珠单抗在对蒽环类新辅助化疗耐药的高危早期三阴性乳腺癌（TNBC）患者中的安全性和有效性。方法：在这项单臂、开放标签的II期试验中，蒽环类药物治疗后有残留病灶的I-III期TNBC患者接受了每三周一次、共四个周期的多西他赛（100 mg/m2 IV）和帕博利珠单抗（200 mg IV）新辅助治疗。在第2-4周期治疗前三天，患者接受腺病毒介导的白细胞介素-12（ADV/IL-12）基因疗法瘤内注射。主要终点为病理完全缓解（pCR）。次要终点为安全性和毒性评估。相关分析包括免疫表型分析和细胞因子测量。结果：共招募了8名患者；一半患者接受了起始剂量为5 x 10^11病毒颗粒（VP）、体积为2mL的ADV/IL-12瘤内注射。由于发生不良事件（AE），其余4名患者接受了3 x 10^11病毒颗粒的剂量。由于毒性问题，该试验被提前终止，87.5%的患者经历了≥3级不良事件，包括两例治疗相关死亡。仅有一名（12.5%）接受较低剂量ADV/IL-12的患者达到了pCR。仅在达到pCR的患者中观察到CCL4水平升高。结论：多西他赛、帕博利珠单抗和瘤内ADV/IL-12的联合治疗与高全身毒性和极低疗效相关。这些结果强调，在将免疫增强细胞因子整合到新辅助方案中时，需要进行谨慎的剂量优化和患者选择。本研究的转化见解为未来在免疫耐药型TNBC中设计更安全的基于IL-12的策略提供了依据。

### 第二部分 AI 大师评价

本项INTEGRAL研究旨在探索化疗、免疫检查点抑制剂与瘤内基因疗法三联方案在难治性三阴性乳腺癌中的潜力。然而，结果显示该方案具有显著的全身毒性，导致87.5%的受试者出现严重不良事件及两例死亡，试验被迫提前终止。尽管观察到个别缓解病例及CCL4相关免疫生物标志物变化，但极高的安全风险表明在临床应用中整合强效细胞因子需极其严谨的剂量滴定。该研究为未来免疫耐药型肿瘤的IL-12疗法设计提供了关键的负面教训和安全边界参考。

---

## 8. 软组织肿瘤的转录组亚组与形态学亚型、基因组特征及预后相关

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41661217)
**期刊：** Clinical cancer research : an official journal of the American Association for Cancer Research
**PMID：** 41661217
**DOI：** 10.1158/1078-0432.CCR-25-3740

### 第一部分 原文与翻译

**英文原标题：** Transcriptomic subgroups in soft tissue tumors correlate with morphologic subtype, genomic features, and outcome.

> **英文摘要：**
> PURPOSE: Soft tissue tumors (STT) are highly heterogeneous neoplasms with more than 100 recognized subtypes, many of which lack reliable diagnostic or prognostic markers. We aimed to evaluate the clinical utility of transcriptome sequencing (RNA-seq) in classifying STT and identifying prognostically relevant subgroups. EXPERIMENTAL DESIGN: We performed RNA-seq on 704 tumors representing 56 histologic subtypes, integrating global gene expression (GGE) profiles, fusion transcript detection, genomic features, and clinicopathologic data. Unsupervised clustering and machine learning approaches were used to refine tumor classification and identify prognostic transcriptomic signatures. RESULTS: We identified more than 200 pathogenic gene fusion transcripts, including 40 not previously described. Strong GGE profiles were seen for many morphologic subtypes, especially for those characterized by specific gene fusions. Sarcomas with complex genomes, such as myxofibrosarcoma, undifferentiated pleomorphic sarcoma, and leiomyosarcoma (LMS), showed less distinct GGE profiles, and for LMS subclusters correlating with genomic profiles were seen. On the basis of GGE profiles and other data, the diagnosis was changed in 5.7% of the cases. Comparison with follow-up data identified transcriptional subclusters among sarcomas with complex genomes that correlated with metastasis-free survival. CONCLUSIONS: Transcriptomic profiling enhances diagnostic precision, uncovers novel oncogenic fusions, and provides prognostic information in STT. Still, the results of the current study suggest that, due to the morphologic and clinical diversity of these tumors, multicenter collaborative studies are needed to fully explore the potential of RNA-seq in STT.

> **中文摘要：**
> 目的：软组织肿瘤 (STT) 是高度异质性的肿瘤，包含 100 多种已公认的亚型，其中许多亚型缺乏可靠的诊断或预后标志物。本研究旨在评估转录组测序 (RNA-seq) 在 STT 分类和鉴定预后相关亚组中的临床应用价值。实验设计：我们对代表 56 种组织学亚型的 704 例肿瘤进行了 RNA-seq，整合了全局基因表达 (GGE) 图谱、融合转录本检测、基因组特征和临床病理数据。采用无监督聚类和机器学习方法来完善肿瘤分类并识别具有预后意义的转录组特征。结果：我们鉴定了 200 多种致病性基因融合转录本，其中包括 40 种此前未描述过的转录本。许多形态学亚型表现出强烈的 GGE 图谱特征，尤其是那些具有特异性基因融合特征的亚型。具有复杂基因组的肉瘤（如粘液纤维肉瘤、未分化多形性肉瘤和平滑肌肉瘤 [LMS]）显示的 GGE 图谱特征较不明显，而对于 LMS，观察到了与基因组图谱相关的亚群。基于 GGE 图谱和其他数据，5.7% 的病例诊断发生了改变。与随访数据的对比分析在具有复杂基因组的肉瘤中识别出与无转移生存期相关的转录亚群。结论：转录组分析增强了诊断精准度，揭示了新型致癌融合，并为 STT 提供了预后信息。尽管如此，本研究结果表明，由于这些肿瘤的形态和临床多样性，仍需要多中心协作研究来充分探索 RNA-seq 在 STT 中的潜力。

### 第二部分 AI 大师评价

本研究通过对704例软组织肿瘤进行大规模转录组测序，证明了RNA-seq在提升诊断准确性和发现新型致癌融合基因方面的显著价值，成功修正了5.7%的临床诊断。研究深入探讨了基因组复杂肉瘤（如LMS）的转录特征与临床预后的关联，为异质性极强的肉瘤提供了更精准的分层工具。尽管展示了强大的临床应用潜力，但研究也指出受限于样本多样性，未来仍需多中心合作以完善这一技术在临床路径中的全面整合。

---

## 9. 尿液生物标志物客观测量非肌层浸润性膀胱癌的微小残留病灶

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41661209)
**期刊：** Clinical cancer research : an official journal of the American Association for Cancer Research
**PMID：** 41661209
**DOI：** 10.1158/1078-0432.CCR-25-3395

### 第一部分 原文与翻译

**英文原标题：** Urinary Biomarkers Objectively Measure Minimal Residual Disease in Non-Muscle-Invasive Bladder Cancer.

> **英文摘要：**
> PURPOSE: To determine if carcinoma in situ (CIS) is a sufficient measure of minimal residual disease (MRD) in non-muscle-invasive bladder cancer (NMIBC) and to evaluate alternative measures of MRD. EXPERIMENTAL DESIGN: We evaluated concordance of CIS on TURBT and radical cystectomy (RC) to determine eradication rates of clinical CIS (cCIS) by TURBT alone and rates of occult pathologic CIS (pCIS) seen only in RC specimens. We studied a prospective cohort of patients with BCG-naive high-grade NMIBC to evaluate pretreatment urinary cytology and urinary tumor (ut)DNA as alternative biomarkers. RESULTS: Eradication of CIS was seen in 20% of patients (78/383). Positive urinary cytology, but not cCIS, was associated with pCIS. In our prospective cohort (n=173), abnormal pre-BCG urine cytology, but not pre-BCG cCIS, had worse high-grade recurrence-free survival (HG-RFS) (hazard ratio [HR] 3.56 95%, confidence interval [CI] 1.74 - 7.31, p<0.001). Median follow-up was 1.8 years (95% CI: 1.3-2.2). Among those with utDNA available, 84% (56/67) had sufficient DNA for genomic profiling. The 2-year HG-RFS rate in patients without an oncogenic alteration (n=17) in their pre-BCG urine was 100% versus 60% (95% CI: 46%-78%) in patients with detectable oncogenic alterations (n=38) (p=0.004). Area under the curve values for predicting 2-year HG-RFS were 0.52 for cCIS, 0.68 for cytology, and 0.74 for utDNA. CONCLUSIONS: We found ~20% eradication of cCIS from TURBT alone. cCIS was a poor metric of MRD, performing worse than abnormal pretreatment urinary cytology and utDNA. These urine biomarkers are more objective MRD measures than cCIS for NMIBC risk stratification and treatment assessment.

> **中文摘要：**
> 目的：确定原位癌（CIS）是否是衡量非肌层浸润性膀胱癌（NMIBC）微小残留病灶（MRD）的充分指标，并评估MRD的其他替代衡量指标。实验设计：我们评估了经尿道膀胱肿瘤切除术（TURBT）与根治性膀胱切除术（RC）中CIS的一致性，以确定仅通过TURBT清除临床原位癌（cCIS）的比例，以及仅在RC标本中发现的隐匿性病理原位癌（pCIS）的比例。我们研究了一个未接受过卡介苗（BCG）治疗的高级别NMIBC患者的前瞻性队列，以评估治疗前尿细胞学和尿肿瘤DNA（utDNA）作为替代生物标志物的价值。结果：20%的患者（78/383）实现了CIS的清除。尿细胞学阳性与pCIS相关，而cCIS则不然。在我们的前瞻性队列（n=173）中，BCG治疗前尿细胞学异常（而非治疗前cCIS）与较差的高级别无复发生存期（HG-RFS）相关（风险比 [HR] 3.56，95% 置信区间 [CI] 1.74 - 7.31，p<0.001）。中位随访时间为1.8年（95% CI: 1.3-2.2）。在有utDNA可用的患者中，84%（56/67）有足够的DNA进行基因组分析。BCG治疗前尿液中无致癌改变的患者（n=17）的2年HG-RFS率为100%，而检测到致癌改变的患者（n=38）为60%（95% CI: 46%-78%）（p=0.004）。预测2年HG-RFS的曲线下面积（AUC）值，cCIS为0.52，细胞学为0.68，utDNA为0.74。结论：我们发现仅通过TURBT约可清除20%的cCIS。cCIS是衡量MRD的较差指标，其表现逊于治疗前异常的尿细胞学和utDNA。对于NMIBC的风险分层和治疗评估，这些尿液生物标志物是比cCIS更客观的MRD衡量指标。

### 第二部分 AI 大师评价

本研究挑战了临床原位癌（cCIS）作为NMIBC微小残留病灶（MRD）评估标准的可靠性。通过对比病理结果和长期生存数据，研究证实了治疗前尿细胞学及尿肿瘤DNA（utDNA）在预测复发和识别隐匿性病灶方面显著优于cCIS，其中utDNA的预测效能（AUC 0.74）最为突出。该发现为膀胱癌提供了更客观的分子层面MRD衡量工具，对于优化临床风险分层和精准监测具有重要的实践指导意义。

---

## 10. 西酞普兰通过调节 C5aR1+ 肿瘤相关巨噬细胞发挥免疫依赖性抗肿瘤作用

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41661166)
**期刊：** eLife
**PMID：** 41661166
**DOI：** 10.7554/eLife.103016

### 第一部分 原文与翻译

**英文原标题：** Citalopram exhibits immune-dependent anti-tumor effects by modulating C5aR1 TAMs.

> **英文摘要：**
> Administration of selective serotonin reuptake inhibitors (SSRIs) is associated with a reduced cancer risk and shows significant anti-tumor effects across multiple tumor types, suggesting the potential for repurposing SSRIs in cancer therapy. Nonetheless, the specific molecular target and mechanism of action of SSRIs remain to be fully elucidated. Here, we reveal that citalopram exerts an immune-dependent anti-tumor effect in hepatocellular carcinoma (HCC). Interestingly, the anti-HCC effects of citalopram are not reliant on its conventional target, the serotonin transporter. Through various drug repurposing approaches, including global reverse gene expression profiling, drug affinity responsive target stability assay, and molecular docking, the complement component 5a receptor 1 (C5aR1) is identified as a new target of citalopram. C5aR1 is predominantly expressed by tumor-associated macrophages, and citalopram treatment enhances local macrophage phagocytosis and elicits CD8 T anti-tumor immunity. C5aR1 deficiency or depletion of CD8 T cells hinders the anti-HCC effects of citalopram. Collectively, our study reveals the immunomodulatory roles of citalopram in inducing anti-tumor immunity and provides a basis for considering the repurposing of SSRIs as promising anticancer agents for HCC treatment.

> **中文摘要：**
> 选择性 5-羟色胺再摄取抑制剂 (SSRIs) 的给药与癌症风险降低相关，并在多种肿瘤类型中显示出显著的抗肿瘤效果，提示了将 SSRIs 重新利用于癌症治疗的潜力。尽管如此，SSRIs 的具体分子靶点和作用机制仍有待充分阐明。在此，我们揭示了西酞普兰在肝细胞癌 (HCC) 中发挥免疫依赖性的抗肿瘤作用。有趣的是，西酞普兰的抗 HCC 作用并不依赖于其传统靶标——5-羟色胺转运蛋白。通过包括全局反向基因表达谱分析、药物亲和力响应靶标稳定性实验和分子对接在内的多种药物再利用方法，补体成分 5a 受体 1 (C5aR1) 被鉴定为西酞普兰的一个新靶点。C5aR1 主要在肿瘤相关巨噬细胞上表达，西酞普兰处理增强了局部巨噬细胞的吞噬作用，并激发了 CD8+ T 细胞的抗肿瘤免疫。C5aR1 缺失或 CD8+ T 细胞的耗竭会阻碍西酞普兰的抗 HCC 作用。总的来说，我们的研究揭示了西酞普兰在诱导抗肿瘤免疫中的免疫调节作用，并为考虑将 SSRIs 作为肝细胞癌治疗中有前景的抗癌药物进行老药新用提供了依据。

### 第二部分 AI 大师评价

本研究通过先进的药物再利用策略，深入探讨了抗抑郁药物西酞普兰在肝细胞癌中的抗肿瘤潜力，并成功鉴定了补体受体 C5aR1 为其新的分子靶点。研究亮点在于揭示了该药不依赖于传统的 5-羟色胺转运蛋白机制，而是通过重塑肿瘤相关巨噬细胞的功能来激活 CD8+ T 细胞介导的抗肿瘤免疫。该发现不仅阐明了西酞普兰免疫调节的新机制，也为老药新用在肿瘤免疫治疗领域的应用提供了坚实的实验证据和理论支持。

---

## 11. 高级别浆液性卵巢癌单细胞空间图谱揭示 MHC II 类分子是空间肿瘤生态系统和临床结局的关键预测因子

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41661089)
**期刊：** Cancer discovery
**PMID：** 41661089
**DOI：** 10.1158/2159-8290.CD-25-1492

### 第一部分 原文与翻译

**英文原标题：** Single-cell spatial atlas of high-grade serous ovarian cancer uncovers MHC class II as a key predictor of spatial tumor ecosystems and clinical outcomes.

> **英文摘要：**
> The tumor microenvironment in high-grade serous ovarian carcinoma (HGSC) is a complex network of malignant-host cell interactions, yet its orchestration remains poorly understood. We present a single-cell spatial atlas of metastatic HGSC from 280 patients, integrating high-dimensional imaging and molecular profiling. Analyzing 929 single-cell maps, we identify spatial domains with diverse cell compositions and show that immune cell co-infiltration at the tumor-stroma interface impacts clinical outcomes. Using CEFIIRA, we find that tumor cell MHCII expression is a key predictor of prolonged survival. Validation with deconvoluted, single-cell, and two distinct spatial transcriptomic datasets, along with immunopeptidomic analysis, confirms that MHCII expression correlates with immune activation, antigen presentation, and TCR clonality. Using a patient-derived immuno-oncology platform, we demonstrate that tumor MHCII expression associates with increased CD8+ T cell cytotoxicity after PD-1 blockade, while blocking MHCII inhibits this activation. Our atlas offers new insights into immune activation, potentially improving patient stratification in HGSC.

> **中文摘要：**
> 高级别浆液性卵巢癌（HGSC）中的肿瘤微环境是恶性细胞与宿主细胞相互作用的复杂网络，但其组织架构仍不甚清楚。我们展示了一个来自 280 名患者的转移性 HGSC 单细胞空间图谱，整合了高维度成像和分子谱分析。通过分析 929 个单细胞地图，我们识别了具有多样细胞组成的空间域，并表明肿瘤-基质界面处的免疫细胞共同浸润影响临床结局。利用 CEFIIRA 工具，我们发现肿瘤细胞 MHCII 的表达是患者生存期延长的关键预测因子。通过反卷积、单细胞和两个独立的空间转录组数据集以及免疫肽组学分析进行的验证，证实了 MHCII 的表达与免疫激活、抗原呈递和 TCR 克隆性相关。利用患者来源的免疫肿瘤学平台，我们证明肿瘤 MHCII 表达与 PD-1 阻断后 CD8+ T 细胞毒性的增加相关，而阻断 MHCII 则会抑制这种激活。我们的图谱为免疫激活提供了新的见解，有可能改善 HGSC 患者的精准分层。

### 第二部分 AI 大师评价

该研究通过对280名HGSC患者进行大规模单细胞空间图谱分析，成功揭示了肿瘤空间微环境的组织规律。核心创新点在于发现并验证了肿瘤细胞MHC II类分子表达作为临床预后和免疫反应的关键指标，且通过功能性实验明确了其在PD-1阻断疗效中的调节作用。这项工作不仅提供了高质量的卵巢癌空间多组学资源，也为理解肿瘤免疫逃逸机制和开发新的分层诊断策略奠定了坚实基础。

---

## 12. 细胞疗法与双特异性接合器：重新定义针对检查点耐药的策略

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41661081)
**期刊：** Clinical cancer research : an official journal of the American Association for Cancer Research
**PMID：** 41661081
**DOI：** 10.1158/1078-0432.CCR-24-3694

### 第一部分 原文与翻译

**英文原标题：** Cell Therapies and Bispecific Engagers: Redefining Strategies Against Checkpoint Resistance.

> **英文摘要：**
> Most patients with solid tumors either never benefit from immune checkpoint inhibitors (ICIs) or relapse after an initial response, underscoring the need for additional therapies. Clinical and translational evidence points to two complementary strategies to overcome ICI resistance: redirection of effector cells by imposing novel tumor-specificity via engineered T cell receptors (TCRs), chimeric antigen receptors (CARs), and CD3/TCR engagers, and augmentation of endogenous responses by tumor infiltrating lymphocyte (TIL) therapy, cytokine support, and microenvironment remodeling. This review integrates emerging signals across platforms and examines why some designs succeed while others stall. Therapeutic efficacy depends on tumor target features and the surrounding microenvironment. Clinical efficacy is emerging when (i) tumor targets show high density and uniformity with restriction to malignant cells, (ii) antigen presentation can be harnessed for TCR-based strategies or bypassed with CARs and engagers, and (iii) the tumor contexture is permissive or convertible with regional delivery and stromal, vascular, or myeloid modulation. Engineering solutions such as tuned costimulation, cytokine armoring, and resistance to suppression improve effector expansion and persistence. Safe and scalable delivery requires exposure control and operational solutions in manufacturing and logistics. Step-up dosing and optimized routes can limit peak exposure and resource intensity. Autologous manufacturing and time to treatment remain limiting, whereas off-the-shelf platforms improve logistics. For patients, near-term progress will rely on biomarker-guided selection and pragmatic trials that address sequencing and bridging, while benchmarking durability across modalities.

> **中文摘要：**
> 大多数实体瘤患者要么从未从免疫检查点抑制剂（ICIs）中获益，要么在初始反应后复发，这凸显了对额外疗法的需求。临床和转化证据指出了克服 ICI 耐药的两种互补策略：通过工程化 T 细胞受体（TCRs）、嵌合抗原受体（CARs）和 CD3/TCR 接合器施加新的肿瘤特异性来重定向效应细胞；以及通过肿瘤浸润淋巴细胞（TIL）疗法、细胞因子支持和微环境重塑来增强内源性反应。本综述整合了各平台新兴的信号，并探讨了为什么某些设计能取得成功而另一些则停滞不前。治疗效果取决于肿瘤靶点特征和周围微环境。当满足以下条件时，临床疗效正在显现：（i）肿瘤靶点表现出高密度和均匀性，且仅限于恶性细胞；（ii）抗原呈递可用于基于 TCR 的策略，或通过 CARs 和接合器绕过；以及（iii）肿瘤背景允许或通过局部递送以及基质、血管或骨髓调节可转化。诸如调谐共刺激、细胞因子武装和抗抑制性等工程化解决方案可改善效应细胞的扩增和持久性。安全且可扩展的递送需要暴露控制以及制造和物流方面的运营解决方案。阶梯剂量和优化的给药途径可以限制峰值暴露和资源强度。自体制造和治疗时间仍然是限制因素，而通用型平台则改善了物流。对于患者而言，近期进展将依赖于生物标志物指导的选择和解决测序与桥接的务实试验，同时跨调节方式对持久性进行基准测试。

### 第二部分 AI 大师评价

这篇综述系统总结了细胞疗法（如CAR-T、TCR-T、TIL）和双特异性抗体在应对免疫检查点抑制剂耐药方面的最新研究进展与转化医学证据。文章深入探讨了肿瘤抗原特征、微环境调控及工程化改良对治疗效果的关键影响，指出高靶点密度和微环境可塑性是取得临床突破的核心要素。作者不仅关注生物学机制，还前瞻性地分析了制造工艺、物流交付及临床试验设计等实际瓶颈，为实体瘤免疫治疗的下一阶段发展提供了综合性的理论框架。

---

## 13. 肌纤维母细胞通过诱导神经可塑性促进胰腺炎症和癌症进展

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41661076)
**期刊：** Cancer discovery
**PMID：** 41661076
**DOI：** 10.1158/2159-8290.CD-25-1337

### 第一部分 原文与翻译

**英文原标题：** Myofibroblasts induce neuroplasticity to promote pancreatic inflammation and cancer progression.

> **英文摘要：**
> Pancreatic ductal adenocarcinoma (PDAC) co-opts the peripheral nervous system through nerve hypertrophy, axonogenesis and perineural invasion, and these processes correlate with patient morbidity and mortality. Prior work has shown that autonomic nerves directly modulate neoplastic cells in PDAC, but whether cancer-associated fibroblasts (CAFs) participate in neural remodeling is unknown. Using thick tissue sections, we identified dense neo-innervation near myofibroblastic CAFs (myCAFs) in preinvasive Pancreatic Intraepithelial Neoplasms (PanINs). Mechanistically, TGF-β produced during inflammation and neoplasia triggers myofibroblast formation, and myCAFs produce axon guidance molecules that recruit sympathetic nerves. Norepinephrine released by sympathetic nerves activates myofibroblast cultures in vitro, and sympathetic nerve depletion impairs stromal activation and PDAC growth in vivo. A chemogenetic model confirmed that fibroblast-specific α1-adrenergic signaling exacerbated pancreatic inflammation and neoplasia. Therefore, beyond direct epithelial effects, sympathetic nerves promote pancreatitis and PDAC by co-opting myofibroblasts and myCAFs as disease amplifiers, highlighting CAF subtype-specific stromal interactions as putative therapeutic targets.

> **中文摘要：**
> 胰腺导管腺癌 (PDAC) 通过神经肥大、轴突发生和神经周围浸润利用周围神经系统，这些过程与患者的发病率和死亡率相关。先前的工作已经表明，自主神经直接调节 PDAC 中的肿瘤细胞，但癌症相关成纤维细胞 (CAFs) 是否参与神经重塑尚不清楚。利用厚组织切片，我们在浸润前胰腺上皮内瘤变 (PanINs) 的肌纤维母细胞型 CAFs (myCAFs) 附近发现了密集的神经新生。从机制上讲，炎症和肿瘤形成过程中产生的 TGF-β 触发了肌纤维母细胞的形成，而 myCAFs 产生轴突引导分子以招募交感神经。交感神经释放的去甲肾上腺素在体外激活肌纤维母细胞培养物，而在体内，交感神经耗竭会损害基质激活和 PDAC 的生长。化学遗传学模型证实，成纤维细胞特异性 α1-肾上腺素能信号传导加剧了胰腺炎症和肿瘤形成。因此，除了直接作用于上皮细胞外，交感神经还通过利用肌纤维母细胞和 myCAFs 作为疾病放大器来促进胰腺炎和 PDAC，突出了 CAF 亚型特异性的基质相互作用是潜在的治疗靶点。

### 第二部分 AI 大师评价

本研究揭示了胰腺癌微环境中神经与基质交互的关键机制，阐明了 myCAF 亚型在诱导神经重塑中的核心作用。研究通过厚组织切片成像和化学遗传学模型，证明了 TGF-β/myCAF/轴突引导分子轴招募交感神经，而神经递质去甲肾上腺素又进一步激活基质，形成恶性反馈环路。这一发现突破了以往仅关注神经-肿瘤细胞直接作用的局限，将特定 CAF 亚型及其与神经的相互作用定义为 PDAC 的新型治疗靶点，具有极高的临床转化潜力。

---

## 14. 单细胞空间多组学：技术、方法与生物学应用

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41660845)
**期刊：** Genomics, proteomics & bioinformatics
**PMID：** 41660845
**DOI：** 10.1093/gpbjnl/qzag012

### 第一部分 原文与翻译

**英文原标题：** Single-cell Spatial Multiomics: Technologies, Methods, and Biological Applications.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要。

### 第二部分 AI 大师评价

这篇综述文章系统性地梳理了单细胞空间多组学这一前沿领域的最新进展，重点介绍了相关的高通量检测技术与前沿计算分析方法。文章深入探讨了如何通过整合空间定位信息与多种分子模态（如转录组、蛋白质组等）来精准揭示复杂的组织架构与细胞间的相互作用。作者不仅阐述了该技术在解析生物发育和疾病机理中的广泛应用，还前瞻性地指出了当前面临的技术挑战与未来发展方向。该研究为理解细胞异质性及其微环境提供了重要的技术指南和理论框架。

---

## 15. 癌症患者及幸存者的冠状动脉粥样硬化：美国心脏协会科学声明

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41657216)
**期刊：** Circulation
**PMID：** 41657216
**DOI：** 10.1161/CIR.0000000000001391

### 第一部分 原文与翻译

**英文原标题：** Coronary Atherosclerosis in Patients With Cancer and Survivors: A Scientific Statement From the American Heart Association.

> **英文摘要：**
> There is an emerging convergence between atherosclerotic cardiovascular disease and cancer, driven by shared risk factors and overlapping pathophysiologic mechanisms. Traditional factors, such as smoking, aging, obesity, hypertension, and diabetes, alongside novel markers, such as clonal hematopoiesis of indeterminate potential, not only predispose individuals to both malignancies and coronary atherosclerosis but also amplify the risk of cardiotoxicity from cancer therapies. Inflammatory processes play a central role in atherogenesis, a process further accelerated by oncologic treatments-including chemotherapy (eg, anthracyclines, 5-fluorouracil), targeted and hormone therapies (eg, tyrosine kinase inhibitors, androgen deprivation, aromatase inhibitors), immune checkpoint inhibitors, and radiation therapy (RT)-that contribute to endothelial dysfunction and plaque instability. This scientific statement synthesizes the evidence on the interplay between cancer and coronary atherosclerosis, highlighting advances in noninvasive imaging modalities (ie, cardiac CT, nuclear imaging, cardiac magnetic resonance, echocardiography) for early detection, risk stratification, and surveillance of coronary artery disease in oncologic populations, and examines the role of invasive imaging techniques in guiding revascularization decisions. Given the elevated bleeding and thrombotic risks in these patients, individualized management of post-percutaneous coronary intervention medications and abbreviated dual antiplatelet therapy regimens is emphasized. This scientific statement also addresses knowledge gaps and reinforces the need for more evidence to improve risk stratification for atherosclerotic cardiovascular disease in patients with cancer. The shared pathobiology between coronary atherosclerosis and cancer necessitates an integrated, multidisciplinary approach to screening, diagnosis, and management.

> **中文摘要：**
> 在共同风险因素和重叠病理生理机制的驱动下，动脉粥样硬化性心血管疾病与癌症之间正呈现出一种新兴的交集。传统因素（如吸烟、老龄化、肥胖、高血压和糖尿病）以及新型标志物（如意义不明的克隆性造血）不仅使个体易患恶性肿瘤和冠状动脉粥样硬化，还放大了癌症治疗产生心脏毒性的风险。炎症过程在动脉粥样硬化形成中起着核心作用，而肿瘤治疗——包括化疗（如蒽环类药物、5-氟尿嘧啶）、靶向和激素疗法（如酪氨酸激酶抑制剂、雄激素剥夺、芳香化酶抑制剂）、免疫检查点抑制剂和放射治疗（RT）——通过导致内皮功能障碍和斑块不稳定性，进一步加速了这一过程。本科学声明综合了关于癌症与冠状动脉粥样硬化相互作用的证据，重点介绍了无创成像技术（即心脏CT、核医学显像、心脏磁共振、超声心动图）在肿瘤人群冠心病早期检测、风险分层和监测方面的进展，并探讨了有创成像技术在指导血运重建决策中的作用。鉴于此类患者出血和血栓风险升高，声明强调了经皮冠状动脉介入术后药物的个体化管理以及简化的双重抗血小板治疗方案。该科学声明还指出了知识空白，并强调需要更多证据来改善癌症患者动脉粥样硬化性心血管疾病的风险分层。冠状动脉粥样硬化与癌症之间共同的病理生物学特征要求采取综合的、多学科的方法进行筛查、诊断和管理。

### 第二部分 AI 大师评价

该声明系统性地阐述了肿瘤学与心脏病学的交叉前沿，明确了共享风险因素（如CHIP）和肿瘤治疗相关炎症在加速冠状动脉粥样硬化中的核心作用。文章重点突出了无创影像技术在癌症患者风险分层与监测中的应用价值，并针对该群体复杂的出血与血栓矛盾，提出了极具临床操作性的个体化抗血小板治疗建议。尽管在特定肿瘤类型的长期证据方面仍存缺口，但该声明为建立多学科协作的肿瘤心脏病学诊疗模式提供了权威的理论支撑与实践指南。

---

## 16. 散发性与遗传性神经内分泌肿瘤中独特的表观遗传老化特征

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41656300)
**期刊：** Clinical epigenetics
**PMID：** 41656300
**DOI：** 10.1186/s13148-026-02069-1

### 第一部分 原文与翻译

**英文原标题：** Distinct epigenetic aging in sporadic and hereditary neuroendocrine neoplasms.

> **英文摘要：**
> BACKGROUND: Epigenetic clocks assess DNA aging based on DNA methylation. We aimed to study the utility of methylation clocks in understanding the distinct characteristics of sporadic and hereditary neuroendocrine neoplasms (NEN). METHODS: Epigenetic age and acceleration were calculated based on Horvath multi-tissue, Levine, and Hannum clocks, and compared by genetic predisposition and NEN grading (WHO-defined G1, G2 and G3). RESULTS: Following quality assessment and filtering of the data, 93/96 samples were analyzed. Of them, 41/93, 42/93, and 10/93 were sporadic, multiple endocrine neoplasia 1 (MEN1) and von Hippel-Lindau (VHL)-related NEN, respectively. Forty-eight (48/93) were pancreatic NEN (PanNEN). mDNA age positively correlated with chronological age based on three different clock algorithms, but stronger correlations were found in the hereditary NEN subgroups (Horvath clock, r = 0.65, p < 0.001 for MEN1-relatd NEN, and r = 0.86, p = 0.002 in VHL-related NEN). Epigenetic age acceleration was higher in sporadic NEN compared to hereditary NEN, both based on chronological age-adjusted epigenetic age (Hannum clock, sporadic vs. MEN, p = 0.03; sporadic vs. VHL, p = 0.0002), and based on the difference between epigenetic age and chronological age (Hannum clock, sporadic vs. MEN1, p = 0.009; sporadic vs. VHL, p = 0.0005). Finally, epigenetic age (p = 0.04) and age acceleration (p = 0.03) were higher among adult patients with NEN (G2/3 vs. G1). CONCLUSIONS: Epigenetic age and age acceleration analysis demonstrate distinct patterns in sporadic and hereditary NEN, suggesting lower impact of epigenetic alteration or DNA aging in the pathogenesis of hereditary NEN.

> **中文摘要：**
> 背景：表观遗传钟基于 DNA 甲基化评估 DNA 老化。本研究旨在探讨甲基化钟在理解散发性和遗传性神经内分泌肿瘤 (NEN) 独特特征方面的应用价值。方法：基于 Horvath 多组织钟、Levine 钟和 Hannum 钟计算表观遗传年龄及老化加速情况，并根据遗传易感性和 NEN 分级（WHO 定义的 G1、G2 和 G3）进行比较。结果：经过质量评估和数据过滤，对 93/96 个样本进行了分析。其中，散发性、1 型多发性内分泌腺瘤病 (MEN1) 相关和希佩尔-林道 (VHL) 相关 NEN 分别为 41/93、42/93 和 10/93。48 例 (48/93) 为胰腺 NEN (PanNEN)。基于三种不同的时钟算法，DNA 甲基化年龄与实足年龄呈正相关，但在遗传性 NEN 亚组中相关性更强（MEN1 相关 NEN：Horvath 钟，r = 0.65，p < 0.001；VHL 相关 NEN：r = 0.86，p = 0.002）。与遗传性 NEN 相比，散发性 NEN 的表观遗传年龄加速更高，无论是基于实足年龄调整后的表观遗传年龄（Hannum 钟，散发性 vs. MEN，p = 0.03；散发性 vs. VHL，p = 0.0002），还是基于表观遗传年龄与实足年龄之差（Hannum 钟，散发性 vs. MEN1，p = 0.009；散发性 vs. VHL，p = 0.0005）。最后，在成年 NEN 患者中（G2/3 vs. G1），表观遗传年龄 (p = 0.04) 和年龄加速 (p = 0.03) 更高。结论：表观遗传年龄及年龄加速分析揭示了散发性和遗传性 NEN 的独特模式，提示在遗传性 NEN 的发病机制中，表观遗传改变或 DNA 老化的影响较小。

### 第二部分 AI 大师评价

本研究通过对比多种表观遗传钟模型，揭示了散发性与遗传性神经内分泌肿瘤（NEN）在分子老化路径上的显著差异。核心发现指出，散发性NEN表现出更显著的表观遗传年龄加速，且该加速与肿瘤恶性程度（G2/3级）正相关，而遗传性NEN的老化特征则与实际年龄更为接近。这一研究结果有力地证明了不同遗传背景下NEN发病机制的异质性，提示遗传性NEN可能更多受驱动突变影响而非表观遗传累积，为NEN的精准分类与病理学研究提供了重要补充。

---

## 17. 更正：miR-548k 通过调节肿瘤微环境驱动与染色体 11q13.3 扩增相关的淋巴结转移。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41656277)
**期刊：** Molecular cancer
**PMID：** 41656277
**DOI：** 10.1186/s12943-026-02586-w

### 第一部分 原文与翻译

**英文原标题：** Correction: The chromosome 11q13.3 amplification associated lymph node metastasis is driven by miR-548k through modulating tumor microenvironment.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

该文献是针对发表在《Molecular Cancer》上关于 miR-548k 驱动淋巴结转移研究的一项更正说明。原研究主要探讨了染色体 11q13.3 扩增区域内的 miR-548k 如何通过调节肿瘤微环境促进癌症进展。此类更正公告在医学学术界至关重要，旨在修正原始论文中的数据、图表或文字偏差，以维护研究结论的严谨性和科研诚信，确保后续相关肿瘤机制研究能够基于准确的实验结果。

---

## 18. 食管癌表观遗传疗法的研究进展

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41656242)
**期刊：** Clinical epigenetics
**PMID：** 41656242
**DOI：** 10.1186/s13148-026-02073-5

### 第一部分 原文与翻译

**英文原标题：** Advances in epigenetic therapy for esophageal cancer.

> **英文摘要：**
> Esophageal cancer is a highly aggressive malignant tumor of the digestive tract, with significant heterogeneity in its pathogenesis and clinical manifestations. Despite advances in treatment strategies such as surgery, chemotherapy, and radiotherapy, the prognosis of esophageal cancer remains poor. In recent years, increasing evidence has shown that epigenetic regulation plays a critical role in the occurrence and development of esophageal cancer. Epigenetic mechanisms, including DNA methylation, histone modification, and non-coding RNA, can regulate gene expression without changing the DNA sequence and are involved in a variety of biological processes, including cell proliferation, apoptosis, and invasion. Abnormal epigenetic alterations are not only key drivers of tumorigenesis but also promising biomarkers and therapeutic targets. This review focuses on the epigenetic mechanisms involved in esophageal cancer and summarizes the latest progress in epigenetic-based therapeutic strategies, including the development and application of DNA methyltransferase inhibitors, histone deacetylase inhibitors, and drugs targeting non-coding RNAs. Moreover, it discusses the challenges and future prospects of epigenetic therapy in the clinical management of esophageal cancer.

> **中文摘要：**
> 食管癌是一种极具侵袭性的消化道恶性肿瘤，其发病机制和临床表现具有显著的异质性。尽管在手术、化疗和放疗等治疗策略方面取得了进展，但食管癌的预后仍然较差。近年来，越来越多的证据表明，表观遗传调控在食管癌的发生和发展中发挥着关键作用。表观遗传机制（包括 DNA 甲基化、组蛋白修饰和非编码 RNA）可以在不改变 DNA 序列的情况下调节基因表达，并参与包括细胞增殖、凋亡和侵袭在内的多种生物过程。异常的表观遗传改变不仅是肿瘤发生的关键驱动因素，也是极具前景的生物标志物和治疗靶点。本综述重点关注涉及食管癌的表观遗传机制，并总结了基于表观遗传学的治疗策略的最新进展，包括 DNA 甲基转移酶抑制剂、组蛋白脱乙酰酶抑制剂以及针对非编码 RNA 药物的开发和应用。此外，本文还讨论了表观遗传疗法在食管癌临床管理中所面临的挑战和未来的前景。

### 第二部分 AI 大师评价

本文全面综述了表观遗传调控机制在食管癌病理生理过程中的关键作用，系统探讨了DNA甲基化、组蛋白修饰及非编码RNA异常如何驱动肿瘤进展。文章重点梳理了DNA甲基转移酶抑制剂和组蛋白脱乙酰酶抑制剂等前沿药物的临床应用现状，并分析了非编码RNA作为新兴治疗靶点的潜力。该评价客观指出了表观遗传疗法在应对食管癌异质性方面的机遇与挑战，为推动食管癌的精准医疗提供了重要的理论支撑与实践指导。

---

## 19. 更正：组蛋白去甲基化酶 KDM4D 通过 HIF1β/VEGFA 信号通路促进胃肠道间质瘤的进展

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41656223)
**期刊：** Molecular cancer
**PMID：** 41656223
**DOI：** 10.1186/s12943-026-02579-9

### 第一部分 原文与翻译

**英文原标题：** Correction: Histone demethylase KDM4D promotes gastrointestinal stromal tumor progression through HIF1β/VEGFA signalling.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无摘要。

### 第二部分 AI 大师评价

该文献是一篇关于组蛋白去甲基化酶 KDM4D 在胃肠道间质瘤（GIST）中作用研究的更正公告。原研究揭示了 KDM4D 作为关键致癌因子，通过调控 HIF1β/VEGFA 信号轴促进肿瘤的恶性进展，为 GIST 的治疗提供了新的分子靶点。此类更正旨在修正原刊载论文中的数据、图表或文字疏漏，体现了学术严谨性，具体的科学贡献应结合原研究论文进行评估。

---

## 20. 工程化TIGIT阻断膜囊泡协同微波消融介导肝转移瘤的清除

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41655262)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41655262
**DOI：** 10.1002/advs.202522918

### 第一部分 原文与翻译

**英文原标题：** Engineered TIGIT-Blockade Membrane Vesicles Synergize with Microwave Ablation to Mediate Liver Metastases Eradication.

> **英文摘要：**
> Microwave ablation (MWA) represents a highly effective and clinically significant therapeutic modality for the treatment of liver metastases. The proliferation of disseminated tumor cells within the peri-necrotic transition zone (TZ) is a critical factor contributing to the postablative recurrence; to date, no effective method has been identified to specifically target and eliminate these cells. Here, based on an experimental liver metastases model, we leverage single-cell RNA sequencing and flow cytometry analysis, which reveals that TZ exhibits a VEGF-mediated immunosuppressive microenvironment, characterized by a significant increase of CD155 myeloid cells. We further report the development of engineered cell membrane vesicles encapsulating Bevacizumab, which are fused with TIGIT-expressing membranes and platelet membranes (referred to as Bev@TPNVs). The Bev@TPNVs can specifically target the liver and the TZ, inhibit neovascularization, and restore the anti-tumor functionality of CD8 T cells. Our findings demonstrate that Bev@TPNVs can effectively suppress liver metastasis after MWA. The intrahepatic metastasis burden is reduced by approximately 10-fold compared with the control group, and the survival rate of mice within 70 days reaches 50%. This work has the potential to establish a novel standard treatment paradigm that could revolutionize combined immunotherapy following liver metastasis ablation.

> **中文摘要：**
> 微波消融（MWA）是治疗肝转移瘤的一种高效且具有重要临床意义的治疗手段。坏死灶周边的过渡区（TZ）内播散性肿瘤细胞的增殖是导致消融后复发的关键因素；迄今为止，尚未发现能特异性靶向并清除这些细胞的有效方法。在本研究中，基于实验性肝转移模型，我们利用单细胞RNA测序和流式细胞术分析揭示，过渡区呈现出一种由VEGF介导的免疫抑制微环境，其特征是CD155+骨髓源性细胞显著增加。我们进一步报道了一种封装贝伐珠单抗（Bevacizumab）的工程化细胞膜囊泡的开发，该囊泡由表达TIGIT的细胞膜与血小板膜融合而成（简称为Bev@TPNVs）。Bev@TPNVs能够特异性靶向肝脏及过渡区，抑制血管新生，并恢复CD8+ T细胞的抗肿瘤功能。我们的研究结果表明，Bev@TPNVs能有效抑制微波消融后的肝转移。与对照组相比，肝内转移负荷降低了约10倍，且小鼠在70天内的存活率达到50%。这项工作有望建立一种全新的标准治疗范式，可能彻底改变肝转移瘤消融后的联合免疫治疗现状。

### 第二部分 AI 大师评价

本研究针对肝转移瘤微波消融后过渡区复发的临床难题，通过单细胞测序深入揭示了VEGF介导的免疫抑制机制。创新性地构建了集成贝伐珠单抗、TIGIT阻断因子及血小板膜靶向特性的工程化囊泡（Bev@TPNVs），实现了精准的病灶靶向与免疫微环境重塑。实验数据显著证明了其在降低肿瘤负荷及提升生存期方面的卓越效力，为消融后的联合免疫治疗提供了极具临床转化潜力的工程化方案。

---

## 21. 金属超分子给药系统赋能脑膜淋巴管桥接的颅内-外周双重免疫调节以逆转胶质母细胞瘤免疫抑制

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41655257)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41655257
**DOI：** 10.1002/advs.202522604

### 第一部分 原文与翻译

**英文原标题：** Metal-Supramolecular Drug Delivery System Empowered Meningeal Lymphatic Vessels-Bridged Intracranial-Peripheral Dual Immune Modulation for Reversing Glioblastoma Immune Suppression.

> **英文摘要：**
> Glioblastoma (GBM) presents significant challenges in treatment due to the presence of the blood-brain barrier (BBB) and immunosuppressive tumor microenvironment (TME). Here, we developed a novel metal-supramolecular delivery system (FLM@VC) that empowers meningeal lymphatic vessels (MLVs)-bridged intracranial-peripheral dual immune modulation to reverse GBM immune suppression. Using coordination-driven self-assembly of lipoic acid (LA), iron ions (Fe), and bovine albumin (BSA), we engineered nanoassemblies with Verubecestat (MK-8931) encapsulated and with vascular endothelial growth factor C (VEGF-C) and c(RGDfK) conjugated. Subcutaneously delivered FLM@VC hijacks the MLVs for brain delivery bypassing the BBB, overcoming the limitations of conventional intravenous administration. Upon tumor accumulation, GSH-responsive disassembly releases MK-8931 to reprogram TAMs from the pro-tumoral M2 to the anti-tumoral M1 phenotype, thereby eliciting proinflammatory cytokine secretion and enhancing phagocytic clearance of GBM cells. Concurrently, VEGF-C-mediated MLV expansion enhances dendritic cell (DC) trafficking to deep cervical lymph nodes (dCLNs), potently priming CD8 T cell responses. This MLVs-bridged intracranial-peripheral dual immunomodulation strategy effectively transforms immunologically "cold" GBM into "hot" tumors, resulting in potent tumor eradication and significantly prolonged survival in orthotopic GBM models. It not only presents a novel paradigm for synergistic GBM immunotherapy but also provides an alternative brain drug delivery approach.

> **中文摘要：**
> 胶质母细胞瘤（GBM）由于血脑屏障（BBB）的存在和免疫抑制肿瘤微环境（TME），在治疗上面临巨大挑战。在此，我们开发了一种新型金属超分子递送系统（FLM@VC），该系统能够通过脑膜淋巴管（MLVs）桥接颅内-外周双重免疫调节，以逆转GBM的免疫抑制。利用硫辛酸（LA）、铁离子（Fe）和牛血清白蛋白（BSA）的配位驱动自组装，我们构建了封装Verubecestat（MK-8931）并偶联血管内皮生长因子C（VEGF-C）和c(RGDfK)的纳米组装体。皮下递送的FLM@VC利用MLVs进行脑部递送并绕过BBB，克服了传统静脉给药的局限性。在肿瘤蓄积后，谷胱甘肽（GSH）响应性解体释放MK-8931，将肿瘤相关巨噬细胞（TAMs）从促肿瘤的M2型重编程为抗肿瘤的M1型，从而诱导促炎细胞因子分泌并增强对GBM细胞的吞噬清除。同时，VEGF-C介导的MLV扩张增强了树突状细胞（DC）向颈深淋巴结（dCLNs）的迁移，从而强效启动CD8 T细胞反应。这种由MLVs桥接的颅内-外周双重免疫调节策略有效地将免疫“冷”GBM转变为“热”肿瘤，导致原位GBM模型中的肿瘤强效清除并显著延长生存期。这不仅为协同GBM免疫治疗提供了一种新范式，也为脑部药物递送提供了一种替代途径。

### 第二部分 AI 大师评价

该研究开发了一种创新的金属超分子纳米平台FLM@VC，巧妙利用脑膜淋巴管（MLVs）路径绕过血脑屏障，实现了颅内与外周的双重免疫调控。通过GSH响应性释放药物重编程肿瘤相关巨噬细胞，并结合VEGF-C促进DC细胞迁移激活全身免疫，成功将“冷”肿瘤转化为“热”肿瘤。实验结果证明该策略能显著抑制原位胶质母细胞瘤生长并延长生存期，为中枢神经系统疾病的药物递送和协同免疫治疗提供了重要的新思路。

---

## 22. EDTA功能化的纳米级金属有机框架通过放化疗协同和时空匹配的铁螯合用于肿瘤心脏病学

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41655249)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41655249
**DOI：** 10.1002/advs.202521451

### 第一部分 原文与翻译

**英文原标题：** EDTA-Functionalized Nanoscale Metal-Organic Framework for Onco-Cardiology via Radiochemotherapy Synergy and Spatiotemporally Matched Iron Chelation.

> **英文摘要：**
> Doxorubicin (DOX)-induced cardiotoxicity (DIC) has become a major obstacle for clinical application. While ferroptosis represents a critical therapeutic target for DIC, current intervention strategies are limited by spatiotemporal mismatches between DOX accumulation and iron chelation. Here, we engineered an EDTA-functionalized Hf-based metal-organic framework for DOX delivery. This nanoplatform (DME) simultaneously mediates tumor radiochemotherapy synergy and inhibits ferroptosis via real-time iron chelation in cardiac tissue. The EDTA modification not only enhances drug penetration to kill deep-seated tumors, but also endows DME superior iron-scavenging ability, which effectively suppresses mitochondrial-dependent ferroptosis in cardiomyocytes. Using primary cultured neonatal mice cardiomyocytes and a chronic DIC murine model, we demonstrated DME's significant cardioprotection and elucidated its mechanistic basis. Thus, our work establishes a bifunctional nanoplatform that unifies oncotherapy and cardioprotection, offering a spatiotemporally matched iron-chelation strategy for safe and effective clinical use of DOX.

> **中文摘要：**
> 阿霉素（DOX）诱导的心脏毒性（DIC）已成为临床应用的主要障碍。虽然铁死亡是DIC的关键治疗靶点，但目前的干预策略受限于DOX蓄积与铁螯合之间的时空不匹配。在此，我们设计了一种用于DOX递送的EDTA功能化铪（Hf）基金属有机框架。该纳米平台（DME）通过在心脏组织中进行实时铁螯合，同时介导肿瘤放化疗协同作用并抑制铁死亡。EDTA修饰不仅增强了药物渗透以杀伤深层肿瘤，还赋予了DME卓越的铁清除能力，从而有效抑制心肌细胞中线粒体依赖性的铁死亡。通过使用原代培养的小鼠乳鼠心肌细胞和慢性DIC小鼠模型，我们证明了DME显著的心脏保护作用并阐明了其机制基础。因此，我们的工作建立了一个统一肿瘤治疗和心脏保护的双功能纳米平台，为DOX的安全有效临床应用提供了一种时空匹配的铁螯合策略。

### 第二部分 AI 大师评价

该研究针对阿霉素引起的心脏毒性临床难题，开发了一种创新的EDTA功能化Hf-MOF纳米递送系统（DME）。该平台的核心优势在于实现了放化疗协同抗肿瘤与心脏保护的有机统一，特别是通过时空匹配的铁螯合机制有效抑制了心肌细胞的铁死亡。研究不仅在动物模型中证实了其显著的减毒增效作用，还深入探讨了其分子机制，为肿瘤心脏病学领域的药物研发和临床安全用药提供了极具价值的参考。

---

## 23. 线粒体环状RNA CircMT-RNR2通过维护抗氧化防御功能支持伤口修复中的成纤维细胞功能

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41655237)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41655237
**DOI：** 10.1002/advs.202517141

### 第一部分 原文与翻译

**英文原标题：** Mitochondrial CircRNA CircMT-RNR2 Safeguards Antioxidant Defense to Support Fibroblast Functions in Wound Repair.

> **英文摘要：**
> Diabetic foot ulcers (DFUs) are a debilitating diabetes complication in which mitochondrial dysfunction and oxidative stress are prominent but mechanistically unresolved features. Here, we identify the mitochondria-encoded circular RNA (mecciRNA) circMT-RNR2 as a novel modulator of mitochondrial redox homeostasis in human skin wound healing. CircMT-RNR2 is reduced in DFU patient tissue and diabetic mouse wounds, enriched in dermal fibroblasts, and localized to mitochondria. Its loss impairs fibroblast proliferation, migration, extracellular matrix production, and contraction by destabilizing the mitochondrial antioxidant protein PRDX3, leading to elevated oxidative stress, mitochondrial damage, and mitophagy. In murine and human ex vivo wound models, circMT-RNR2 knockdown delays healing, whereas overexpression accelerates repair and boosts antioxidant defenses. These findings position circMT-RNR2 as a mitochondrial guardian of skin healing and a promising therapeutic target for DFU.

> **中文摘要：**
> 糖尿病足溃疡（DFUs）是一种严重的糖尿病并发症，其中线粒体功能障碍和氧化应激是其显著但尚未在机制上得到阐明的特征。在本研究中，我们鉴定出线粒体编码的环状RNA（mecciRNA）circMT-RNR2是人类皮肤伤口愈合中线粒体氧化还原稳态的一种新型调节因子。研究发现，circMT-RNR2在DFU患者组织和糖尿病小鼠伤口中表达降低，主要富集于真皮成纤维细胞并定位于线粒体。其缺失会通过降低线粒体抗氧化蛋白PRDX3的稳定性，进而损害成纤维细胞的增殖、迁移、细胞外基质生成及收缩能力，导致氧化应激升高、线粒体损伤及线粒体自噬。在小鼠及人类离体伤口模型中，敲低circMT-RNR2会延迟愈合，而过表达则能加速修复并增强抗氧化防御。这些发现确立了circMT-RNR2作为皮肤愈合过程中线粒体“守护者”的地位，并使其成为DFU极具前景的治疗靶点。

### 第二部分 AI 大师评价

该研究聚焦于糖尿病足溃疡（DFU）愈合障碍的分子机制，首次揭示了线粒体编码环状RNA circMT-RNR2 在维持成纤维细胞功能中的关键作用。研究通过严谨的体内外实验证明了 circMT-RNR2 通过稳定 PRDX3 蛋白来调节线粒体活性氧水平，从而维持细胞稳态。其创新性在于发现了线粒体基因组来源的非编码RNA在代谢性伤口愈合中的调节价值，为慢性难愈合创面的治疗提供了全新的RNA干预靶点。

---

## 24. 多发性骨髓瘤中 PRKCN 的靶向研究：一种独立于激酶活性协调 mTOR-IRF4 轴的关键驱动因子

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41655233)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41655233
**DOI：** 10.1002/advs.202518975

### 第一部分 原文与翻译

**英文原标题：** Targeting PRKCN, an Essential Driver Orchestrating mTOR-IRF4 Axis Independently of Kinase Activity, in Multiple Myeloma.

> **英文摘要：**
> Multiple myeloma (MM) remains incurable, necessitating development of novel therapeutic targets. Deregulated PRKCN is implicated in solid tumors, while its role in MM remains elusive. Here, PRKCN is identified as a super-enhancer-driven gene associated with adverse prognosis in MM. PRKCN is transactivated by NF-κB signaling intrinsically existing or exogenously provoked. Constitutive or inducible knockdown of PRKCN significantly impairs cell growth and tumorigenicity, while overcoming drug resistance. PRKCN harnesses IRF4 to exert its effect, and in turn, IRF4 directly induces PRKCN transcription, establishing a feed-forward IRF4-PRKCN circuit. Furthermore, PRKCN fosters IRF4 expression by activating mTORC1/C2 signaling pathways via physical interaction with mTOR. Surprisingly, PRKCN modulates mTOR-IRF4 axis and cell growth independently of its acknowledged kinase activity yet requiring activation loop phosphorylation. Intriguingly, PRKCN silencing evokes interferon signaling and confers increased sensitivity to interferon. Finally, targeting PRKCN with an orally bioavailable inhibitor suppresses MM cell growth and overcomes drug resistance in vitro, and elicits robust efficacy in cell line-derived xenografts and a patient-derived xenograft, which is connected with the mitigated PRKCN expression and activation loop phosphorylation as well as blunted mTOR-IRF4 axis. Collectively, our study delineates PRKCN function that links aberrant NF-κB signaling and mTOR-IRF4 axis, supporting clinically targeting PRKCN in MM.

> **中文摘要：**
> 多发性骨髓瘤（MM）目前仍无法治愈，因此有必要开发新型治疗靶点。PRKCN 的失调与实体瘤有关，而其在 MM 中的作用尚不清楚。在本研究中，PRKCN 被鉴定为一种受超级增强子驱动的基因，且与 MM 的不良预后相关。PRKCN 受内在存在或外源激发的 NF-κB 信号通路的转录激活。对 PRKCN 进行组成型或诱导型敲降可显著损害细胞生长和致瘤性，同时克服耐药性。PRKCN 利用 IRF4 发挥作用，反之，IRF4 直接诱导 PRKCN 转录，从而建立了一个前馈的 IRF4-PRKCN 环路。此外，PRKCN 通过与 mTOR 的物理相互作用激活 mTORC1/C2 信号通路，进而促进 IRF4 的表达。令人惊讶的是，PRKCN 对 mTOR-IRF4 轴和细胞生长的调节独立于其公认的激酶活性，但需要激活环（activation loop）的磷酸化。有趣的是，PRKCN 沉默可诱发干扰素信号传导，并增强对干扰素的敏感性。最后，使用口服生物可利用的抑制剂靶向 PRKCN，可在体外抑制 MM 细胞生长并克服耐药性，并在细胞系来源的异种移植物和患者来源的异种移植物中表现出强大的疗效，这与 PRKCN 表达和激活环磷酸化的减轻以及 mTOR-IRF4 轴的减弱有关。总之，我们的研究阐明了 PRKCN 的功能，该功能将异常的 NF-κB 信号传导与 mTOR-IRF4 轴联系起来，支持在临床上靶向 MM 中的 PRKCN。

### 第二部分 AI 大师评价

该研究深入探讨了 PRKCN 在多发性骨髓瘤（MM）发病机制中的核心作用，揭示了其作为超级增强子驱动基因通过 NF-κB 通路被激活，并与 IRF4 形成正反馈环路。最具创新性的发现是 PRKCN 对 mTOR-IRF4 轴的调节并不依赖其经典的激酶活性，而是依赖于激活环的磷酸化及其与 mTOR 的物理相互作用。通过口服小分子抑制剂在多种异种移植模型中表现出显著的抗肿瘤效力，证明了 PRKCN 是攻克 MM 耐药性和改善预后的极具潜力的临床转化靶点。

---

## 25. OCIAD2通过SNX17介导的内吞体再循环至脂筏稳定整合素β1信号传导，并调节头颈部鳞状细胞癌对顺铂的反应

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41655222)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41655222
**DOI：** 10.1002/advs.202515452

### 第一部分 原文与翻译

**英文原标题：** OCIAD2 Stabilizes Integrin β1 Signaling Through SNX17-Mediated Endosomal Recycling to Lipid Rafts and Modulates Cisplatin Response in HNSCC.

> **英文摘要：**
> While cisplatin is a widely used and effective chemotherapeutic agent in the treatment of head and neck squamous cell carcinoma (HNSCC), the molecular mechanisms underlying its resistance remain poorly understood. In this study, we identify OCIA domain containing 2 (OCIAD2) as a central mediator of chemoresistance and tumor progression in HNSCC. Through transcriptomic analysis and Co-immunoprecipitation coupled with mass spectrometry, we demonstrate that OCIAD2 modulates integrin signaling by directly interacting with integrin β1. Mechanistic investigations reveal that OCIAD2 does not regulate integrin β1 at the transcriptional level, but instead stabilizes its protein expression by preventing lysosomal degradation and enhancing its recycling. Importantly, OCIAD2 binds to SNX17 and enhances its association with integrin β1, promoting its recycling to lipid raft-enriched regions of the plasma membrane. By maintaining integrin β1 in these lipid raft compartments, OCIAD2 sustains the activation of the FAK-PI3K-AKT-mTOR signaling cascade, thereby fostering cellular resilience and resistance to cisplatin. Moreover, targeting OCIAD2, either through genetic silencing or RNA-based therapies, significantly sensitizes tumors to cisplatin treatment in preclinical models. This study uncovers a previously unrecognized trafficking-dependent mechanism of drug resistance, suggesting that OCIAD2 may serve as a novel therapeutic target to overcome chemoresistance in HNSCC.

> **中文摘要：**
> 虽然顺铂是治疗头颈部鳞状细胞癌（HNSCC）中广泛使用且有效的化疗药物，但其耐药性的分子机制仍知之甚少。在本研究中，我们鉴定出包含OCIA结构域的蛋白2（OCIAD2）是HNSCC化疗耐药和肿瘤进展的核心介质。通过转录组分析以及结合质谱的免疫共沉淀技术，我们证明了OCIAD2通过与整合素β1（integrin β1）直接相互作用来调节整合素信号传导。机制研究表明，OCIAD2并不在转录水平调节整合素β1，而是通过防止其溶酶体降解并增强其再循环来稳定其蛋白质表达。重要的是，OCIAD2结合SNX17并增强其与整合素β1的结合，促进其向质膜脂筏富集区域的再循环。通过将整合素β1维持在这些脂筏区室中，OCIAD2持续激活FAK-PI3K-AKT-mTOR信号级联反应，从而增强细胞韧性并产生对顺铂的耐药性。此外，在临床前模型中，通过基因沉默或基于RNA的疗法靶向OCIAD2，可显著提高肿瘤对顺铂治疗的敏感性。本研究揭示了一种此前未被认识的依赖于运输的耐药机制，表明OCIAD2可作为克服HNSCC化疗耐药的新型治疗靶点。

### 第二部分 AI 大师评价

本研究深入探讨了OCIAD2在头颈部鳞状细胞癌（HNSCC）顺铂耐药中的关键作用。通过多组学和细胞生物学方法，研究者揭示了OCIAD2通过招募SNX17促进整合素β1向脂筏的内吞再循环，进而持续激活FAK-PI3K-AKT-mTOR通路的分子机制。该研究的创新之处在于发现了蛋白质胞内运输调节与化疗耐药之间的直接联系，为解决HNSCC耐药问题提供了潜在的治疗靶点，具有较强的临床转化价值。

---

## 26. 空间蛋白质基因组学在癌症研究中的整合应用

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41655216)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41655216
**DOI：** 10.1002/advs.202520744

### 第一部分 原文与翻译

**英文原标题：** Integrating Spatial Proteogenomics in Cancer Research.

> **英文摘要：**
> BACKGROUND: Spatial proteogenomics marks a paradigm shift in oncology by integrating molecular analysis with spatial information from both spatial proteomics and other data modalities (e.g., spatial transcriptomics), thereby unveiling tumor heterogeneity and dynamic changes in the microenvironment. METHODS: We systematically reviewed the evolution of spatial proteogenomics, from single-modality profiling to integration with transcriptomics and metabolomics, from the detection of abundant proteins to exploration of "dark proteome" with low abundance or stability, and from analytic software based on traditional machine learning algorithms to advanced artificial intelligence-driven analytical frameworks. RESULTS: Key advances of sub-fields of spatial proteogenomics include: RNA-protein co-localization: Spatial CITE-seq, enabling RNA-protein co-localization to reveal immune microenvironmental patterns and neoantigen distribution. Spatial Proteomics + Spatial Metabolomics: Matrix-assisted laser desorption/ionization imaging (MALDI), overcoming protein detection bottlenecks and capturing metabolic reprogramming. Deep visual proteomics (DVP): achieving unbiased spatial analysis via AI-guided microdissection. Spatial-aware multiplex dark proteome approaches: Examples are nanodroplet processing in one pot for trace samples (NanoPOTS) and proteoform imaging mass spectrometry (PiMS). Multimodal foundation AI models: Examples are KRONOS and HEIST, which integrate multiple data modalities and significantly improve diagnostic precision and therapeutic prediction. CONCLUSIONS AND FUTURE DIRECTIONS: Despite challenges of resolution, standardization, and data complexity, spatial proteomics is advancing rapidly. Together with frontier technologies such as quantum computing, live imaging, and organoid integration, it is driving breakthroughs in cancer diagnosis, personalized immunotherapy, and drug development.

> **中文摘要：**
> 背景：空间蛋白质基因组学通过将分子分析与来自空间蛋白质组学及其他数据模态（如空间转录组学）的空间信息相结合，标志着肿瘤学领域的范式转变，从而揭示了肿瘤异质性和微环境的动态变化。方法：我们系统地回顾了空间蛋白质基因组学的演变，从单模态分析到与转录组学和代谢组学的整合，从检测高丰度蛋白质到探索低丰度或低稳定性的“暗蛋白质组”，以及从基于传统机器学习算法的分析软件到先进的人工智能驱动的分析框架。结果：空间蛋白质基因组学子领域的关键进展包括：RNA-蛋白质共定位：空间CITE-seq，能够实现RNA-蛋白质共定位以揭示免疫微环境模式和新抗原分布。空间蛋白质组学+空间代谢组学：基质辅助激光解吸/电离成像（MALDI），克服了蛋白质检测瓶颈并捕捉代谢重编程。深度视觉蛋白质组学（DVP）：通过人工智能引导的微切割实现无偏见的空间分析。空间感知多重暗蛋白质组学方法：例如用于微量样本的一锅法纳米液滴处理（NanoPOTS）和蛋白质形式成像质谱（PiMS）。多模态基础人工智能模型：例如KRONOS和HEIST，它们整合了多种数据模态，并显著提高了诊断精度和治疗预测。结论与未来方向：尽管在分辨率、标准化和数据复杂性方面存在挑战，但空间蛋白质组学正在迅速发展。结合量子计算、活体成像和类器官整合等前沿技术，它正在推动癌症诊断、个性化免疫治疗和药物开发领域的突破。

### 第二部分 AI 大师评价

本文系统性地综述了空间蛋白质基因组学从单模态分析向多模态整合的演进历程，重点阐述了其在揭示肿瘤异质性与微环境动力学方面的核心价值。文章详细探讨了Spatial CITE-seq、MALDI成像、深度视觉蛋白质组学（DVP）以及针对“暗蛋白质组”的创新探测技术，展示了AI驱动的分析框架如何显著提升诊断与治疗预测的精度。尽管当前技术在分辨率和标准化方面仍面临挑战，但该综述对未来结合量子计算和类器官等前沿领域的展望，为癌症精准医疗的突破提供了重要指引。

---

## 27. 3D生物打印脂肪-心肌模型揭示脂肪细胞肥大在心房功能障碍中的作用

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41655215)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41655215
**DOI：** 10.1002/advs.202516114

### 第一部分 原文与翻译

**英文原标题：** 3D Bioprinted Fat-Myocardium Model Unravels the Role of Adipocyte Hypertrophy in Atrial Dysfunction.

> **英文摘要：**
> Cardiovascular diseases (CVD) are the leading cause of mortality in individuals with obesity. Epicardial adipose tissue (EAT) dysfunction serves as a link between obesity and CVD, promoting inflammatory and metabolic alterations that increase CVD risk. While EAT normally supports cardiac health, obesity-induced adipocyte hypertrophy triggers excessive fatty acid and cytokine release, driving myocardial lipotoxicity and inflammation that impair electrophysiology and metabolism, leading to beating irregularities, insulin resistance, and heart failure. The lack of sufficient EAT in small animal models and the impracticality of using large mammals hinder insights into the effects of EAT hypertrophy on the myocardium. To address this gap, a human-derived 3D bioprinted coculture of obese adipocytes and cardiomyocytes (CMs) is developed using patient-derived adipocytes and human induced pluripotent stem cell (hiPSC)-derived atrial CMs (a-iCMs). This platform enables the investigation of both cell-cell and paracrine interactions between hypertrophic adipocytes and a-iCMs, allowing assessment of electrophysiological, structural, and proteomic changes to uncover mechanisms linking EAT hypertrophy to obesity-related atrial dysfunction. Screening of metformin, a cardioprotective drug, reveals improvement in electrophysiological function in hypertrophic adipocyte-a-iCM cocultures. 3D bioprinted fat-myocardium model provides a high-throughput platform to study obesity-induced atrial dysfunction and facilitate the discovery of therapies for the obese heart.

> **中文摘要：**
> 心血管疾病（CVD）是肥胖个体死亡的首要原因。心外膜脂肪组织（EAT）功能障碍是肥胖与心血管疾病之间的纽带，它促进炎症和代谢改变，从而增加心血管疾病风险。虽然正常情况下EAT支持心脏健康，但肥胖诱导的脂肪细胞肥大触发了过量的脂肪酸和细胞因子释放，驱动心肌脂毒性和炎症，进而损害电生理和代谢，导致跳动不规律、胰岛素抵抗和心力衰竭。由于小动物模型中缺乏足够的EAT，而使用大型哺乳动物研究又不切实际，这阻碍了对EAT肥大对心肌影响的深入了解。为弥补这一空白，本研究利用患者来源的脂肪细胞和人诱导多能干细胞（hiPSC）衍生的心房心肌细胞（a-iCMs），开发了一种人源化3D生物打印肥胖脂肪细胞与心肌细胞的共培养模型。该平台能够研究肥大脂肪细胞与a-iCMs之间的细胞接触及旁分泌相互作用，从而通过评估电生理、结构和蛋白质组学变化，揭示将EAT肥大与肥胖相关心房功能障碍联系起来的机制。对心脏保护药物二甲双胍的筛选显示，肥大脂肪细胞-a-iCM共培养物的电生理功能得到改善。这种3D生物打印的脂肪-心肌模型为研究肥胖诱导的心房功能障碍提供了一个高通量平台，并有助于促进肥胖心脏相关疗法的发现。

### 第二部分 AI 大师评价

该研究利用3D生物打印技术成功构建了基于人源细胞的肥胖脂肪-心房心肌共培养模型，有效填补了传统动物模型在模拟人类心外膜脂肪组织（EAT）病理特征方面的空白。研究深入阐明了脂肪细胞肥大通过分泌促炎因子和脂毒性物质诱导心房电生理功能障碍的机制，并利用二甲双胍验证了该平台在药物筛选中的可行性。该模型具有高度的创新性和临床相关性，为肥胖相关心律失常的机制研究及精准药物开发提供了强有力的工具。

---

## 28. DRD2缺失引起垂体腺瘤发生，且依赖于肠道大肠杆菌的易位

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41655211)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41655211
**DOI：** 10.1002/advs.202504247

### 第一部分 原文与翻译

**英文原标题：** DRD2 Deficiency Underlies Pituitary Adenoma Dependent on Escherichia coli Translocation from the Gut.

> **英文摘要：**
> Pituitary adenoma (PA) are common intracranial tumor types that have harmful effects on human health. However, the pathogenesis of PA remains unclear yet. The intratumoral microbiome has been reported playing an important impact on the occurrence, metastasis, immune monitoring, and drug resistance of various tumors. While normal dopamine receptor D2 (DRD2) expression is enriched in the apical junction of pituitary epithelium and colonic enterocytes, various factors-induced drd2 loss dampened its expression at both sites. DRD2 deficiencies are characterized by chronic hyperprolactinemia, pituitary lactotroph hyperplasia, and prolactinomas in mice, but the role of intratumoral microbiome in prolactinomas is not known. We employed specific pathogen-free (SPF) and germ-free (GF) mice models and patient samples of pituitary adenoma. In the mice pituitary tumor model, we used mice that developed prolactinomas following estradiol treatment or DRD2 deficiencies. Pituitary tumor samples from patients with nonfunctional pituitary adenoma or prolactinomas were obtained after surgical excision. Various molecular, cellular, and sequencing techniques were used to determine the role of intratumoral microbiome in pituitary adenoma. We demonstrate that human patients or murine bearing estradiol-induction or DRD2 loss are all characterized by the presence of live intratumor bacteria in the pituitary adenoma. Using metagenomic next-generation sequencing and mass spectrometry techniques, we confirm that the bacterial species of pituitary tumor tissues is Escherichia coli. In vitro tracing and immunofluorescence assay results showed that the pathobiont Escherichia coli translocates from the gut into the pituitary gland along with DRD2 loss while the blood pituitary barrier were both destroyed in mice. The Escherichia coli are phagocytosed by the microglial cells in the pituitary gland, then activate GSDMD protein releasing HMGB1, and promote the tumorigenesis of pituitary adenoma by activating the MAPK pathway. The depletion of bacteria systemically, microglial depletion or HMGB1 inhibitor ethyl pyruvate rescued prolactinomas. Our findings suggest that DRD2 deficiency underlies pituitary adenoma dependent on Escherichia coli translocation from the gut and activating microglia GSDMD/ HMGB1/MAPK pathway, and provide a novel preclinical rationale for antimicrobial agents, microglial depletion, or HMGB1 inhibitor ethyl pyruvate for the treatment of pituitary adenoma.

> **中文摘要：**
> 垂体腺瘤（PA）是常见的颅内肿瘤类型，对人类健康有显著危害。然而，PA的发病机制尚不清楚。据报道，瘤内微生物组在多种肿瘤的发生、转移、免疫监测和耐药性中发挥着重要影响。虽然正常的多巴胺受体D2（DRD2）表达富集在垂体上皮和结肠肠上皮细胞的顶端连接处，但各种因素诱导的DRD2缺失削弱了其在这两个部位的表达。在小鼠中，DRD2缺失以慢性高催乳素血症、垂体催乳素细胞增生和催乳素瘤为特征，但瘤内微生物组在催乳素瘤中的作用尚不清楚。我们采用了无特定病原体（SPF）和无菌（GF）小鼠模型以及垂体腺瘤患者样本。在小鼠垂体肿瘤模型中，我们使用了雌二醇治疗或DRD2缺失后产生催乳素瘤的小鼠。术后获取了非功能性垂体腺瘤或催乳素瘤患者的垂体肿瘤样本。使用各种分子、细胞和测序技术来确定瘤内微生物组在垂体腺瘤中的作用。我们证明，人类患者或携带雌二醇诱导或DRD2缺失的小鼠在垂体腺瘤中均具有活体瘤内细菌存在的特征。利用宏基因组二代测序和质谱技术，我们确认垂体肿瘤组织的细菌种类是大肠杆菌。体外追踪和免疫荧光实验结果显示，致病性大肠杆菌随着DRD2的缺失从肠道向垂体腺瘤易位，同时小鼠体内的血-垂体屏障被破坏。大肠杆菌被垂体中的小胶质细胞吞噬，随后激活GSDMD蛋白释放HMGB1，并通过激活MAPK通路促进垂体腺瘤的发生。系统性清除细菌、清除小胶质细胞或HMGB1抑制剂乙基丙酮酸盐挽救了催乳素瘤。我们的研究结果表明，DRD2缺失引起垂体腺瘤的发生依赖于大肠杆菌从肠道的易位并激活小胶质细胞GSDMD/HMGB1/MAPK通路，这为使用抗菌药物、清除小胶质细胞或HMGB1抑制剂乙基丙酮酸盐治疗垂体腺瘤提供了新型的临床前理论依据。

### 第二部分 AI 大师评价

该研究创新性地揭示了“肠-垂体轴”在垂体腺瘤发病中的关键机制，证明了DRD2缺失导致的肠道大肠杆菌易位是驱动肿瘤发生的关键因素。研究通过临床样本与小鼠模型结合，详细阐明了大肠杆菌通过激活小胶质细胞GSDMD/HMGB1/MAPK信号通路促进成瘤的生物学路径。该发现不仅深化了对瘤内微生物组功能的认知，还为垂体腺瘤的治疗提供了抗菌干预、免疫调节及HMGB1抑制等极具前景的新策略。

---

## 29. ZBTB21是焦亡与MHC-I抗原呈递的双重抑制因子，促进肿瘤免疫逃逸

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41655210)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41655210
**DOI：** 10.1002/advs.202519836

### 第一部分 原文与翻译

**英文原标题：** ZBTB21 Is a Dual Suppressor of Pyroptosis and MHC-I Antigen Presentation That Promotes Tumor Immune Evasion.

> **英文摘要：**
> Immune checkpoint blockade (ICB) efficacy is limited by tumor-intrinsic immune escape mechanisms. This study identifies the transcription factor ZBTB21 as a central orchestrator of dual immunosuppressive programs. ZBTB21 epigenetically silences gasdermin D (GSDMD)-dependent pyroptosis by restricting STAT1-mediated chromatin accessibility via H3K27ac modulation at the GSDMD locus. Simultaneously, it represses MHC-I antigen presentation by attenuating IRF1 expression and its transactivation capacity. Genetic ablation of ZBTB21 unleashes pyroptotic cell death and enhances tumor antigen presentation, establishing a self-reinforcing cycle that recruits and activates CD8 T cells. This dual activation overcomes ICB resistance in murine models, while B2M deletion ablates efficacy, confirming MHC-I dependency. Pharmacological inhibition of ZBTB21 with dobutamine disrupts its DNA-binding domain, which triggers pyroptotic inflammation and MHC-I upregulation to synergize with anti-PD-1 therapy. Thus, ZBTB21 represents a druggable nexus coordinating pyroptosis resistance and antigen presentation escape, providing a combinatorial strategy to reinvigorate antitumor immunity.

> **中文摘要：**
> 免疫检查点阻断（ICB）的疗效受到肿瘤内在免疫逃逸机制的限制。本研究鉴定出转录因子ZBTB21是双重免疫抑制程序的关键协调者。ZBTB21通过在GSDMD位点进行H3K27ac调节以限制STAT1介导的染色质可及性，从而在表观遗传水平上沉默了gasdermin D (GSDMD)依赖性的细胞焦亡。同时，它通过减弱IRF1的表达及其转录激活能力，抑制了MHC-I抗原呈递。基因敲除ZBTB21可释放焦亡细胞死亡并增强肿瘤抗原呈递，建立起招募并激活CD8+ T细胞的自我强化循环。在小鼠模型中，这种双重激活克服了ICB耐药性，而B2M缺失则消除了疗效，证实了其对MHC-I的依赖性。使用多巴酚丁胺（dobutamine）对ZBTB21进行药理学抑制可破坏其DNA结合域，进而触发焦亡性炎症和MHC-I上调，与抗PD-1治疗产生协同作用。因此，ZBTB21代表了一个协调焦亡抗性和抗原呈递逃逸的可成药枢纽，为重启抗肿瘤免疫提供了联合策略。

### 第二部分 AI 大师评价

该研究揭示了转录因子ZBTB21作为肿瘤免疫逃逸核心调控因子的新机制，其通过表观遗传学手段同时抑制细胞焦亡和MHC-I抗原呈递。研究不仅在分子水平阐明了ZBTB21如何通过影响STAT1和IRF1活性来重塑肿瘤微环境，还发现临床药物多巴酚丁胺具有靶向该因子的潜力。这一发现为克服免疫检查点阻断耐药性提供了坚实的理论依据和具有转化前景的联合治疗新方向。

---

## 30. 母亲的悲恸

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41397200)
**期刊：** Journal of clinical oncology : official journal of the American Society of Clinical Oncology
**PMID：** 41397200
**DOI：** 10.1200/JCO-25-02543

### 第一部分 原文与翻译

**英文原标题：** Mother's Grief.

> **英文摘要：**
> A pediatric oncologist's experience of a patient's death through the new lens of motherhood.

> **中文摘要：**
> 一位儿科肿瘤学家以母亲这一新身份的视角，对一名患者死亡经历的感悟。

### 第二部分 AI 大师评价

该文发表于《临床肿瘤学杂志》（JCO）的艺术与人文专栏，以叙事医学的独特视角探讨了医务人员的情感世界。作者通过双重身份的转换，即身为儿科肿瘤专家的职业属性与身为母亲的私人身份，重新审视了患儿死亡带来的心理冲击与共情深度。文章揭示了临床工作中职业边界与个人情感之间的复杂交织，虽然并非实证性临床研究，但在提升医生职业同理心及应对替代性创伤方面具有深厚的人文启发价值。

---

## 31. 免疫疗法在伴有或不伴有肝转移的错配修复功能完整型结直肠癌患者中的疗效

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/40934442)
**期刊：** Journal of clinical oncology : official journal of the American Society of Clinical Oncology
**PMID：** 40934442
**DOI：** 10.1200/JCO-25-01044

### 第一部分 原文与翻译

**英文原标题：** Immunotherapy Efficacy in Mismatch Repair-Proficient Colorectal Cancer Patients With and Without Liver Metastases.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要。

### 第二部分 AI 大师评价

本研究聚焦于临床难点，探讨了免疫疗法在错配修复功能完整型（pMMR）结直肠癌患者中的应用效果，并特别关注了肝转移这一关键预后因子的影响。由于pMMR患者通常对免疫检查点抑制剂反应不佳，研究不同转移部位导致的免疫微环境差异对疗效的影响具有重要的临床指导意义。该研究发表于顶级期刊JCO，体现了临床上对优化晚期结直肠癌免疫治疗方案的高度关注，尽管目前摘要信息缺失，但其结论可能为特定亚群患者的精准治疗提供有力证据。

---

速递结束，祝您工作愉快！